RISS 검색 - 국내학술지논문 상세보기

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association- National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

참고문헌 (Reference)

1 김인숙 ; 임영석 ; 윤현기 ; 성규보 ; 장명국 ; 최원범 ; 김성훈 ; 이한주 ; 정영화 ; 이영상 ; 서동진, "절제 가능한 간세포암에서 수술 전 경동맥화학색전술의 효과" 대한내과학회 69 (69): 614-621, 2005
2 임태영 ; 정재연 ; 조성원 ; 심성준 ; 김종수 ; 최승준 ; 최정우 ; 권혁춘 ; 이기명 ; 김재근 ; 원제환 ; 유병무 ; 이광재 ; 함기백 ; 김진홍, "비대상성 간경변을 동반한 진행성 간세포암종에서 간동맥내 저용량 5-fluorouracil 및 cisplatin 주입요법의 효과" 대한간학회 12 (12): 65-73, 2006
3 신동현 ; 이현우 ; 곽금연 ; 백용한 ; 최문석 ; 이준혁 ; 고광철 ; 백승운 ; 강원석, "밀란병기 이내로 진단된 간세포암 환자의 사망 원인분석" 대한간암학회 16 (16): 101-107, 2016
4 안민 ; 박중원 ; 신정아 ; 최준일 ; 김태현 ; 김성훈 ; 이우진 ; 박상재 ; 홍은경 ; 김창민, "간접적으로 확인한 간문맥압항진증이 간세포암종 환자의 간절제술 후 합병증 발생과 예후에 미치는 영향" 대한간학회 12 (12): 553-561, 2006
5 Llovet JM, "mRECIST for HCC : performance and novel refinements" 72 : 288-306, 2020
6 Seymour L, "iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics" 18 : e143-e152, 2017
7 Chu HH, "a propensity score matching analysis" 12 : 1116-, 2020
8 Salem R, "Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC : the LEGACY study" 74 : 2342-2352, 2021
9 Mazzaferro V, "Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma : a phase 2 study" 57 : 1826-1837, 2013
10 Salem R, "Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma" 151 : 1155-1163.e2, 2016
11 Kim HY, "Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma" 28 : 1756-1761, 2013
12 Germani G, "Which matters most: number of tumors, size of the largest tumor, or total tumor volume?" 17 (17): S58-S66, 2011
13 Guyatt GH, "What is “quality of evidence” and why is it important to clinicians?" 336 : 995-998, 2008
14 Freeman RB, "Waiting list removal rates among patients with chronic and malignant liver diseases" 6 : 1416-1421, 2006
15 Mehta N, "Wait time of less than 6 and greater than 18months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time “sweet spot”" 101 : 2071-2078, 2017
16 WHO Classification of Tumours Editorial Board, "WHO classification of tumors: digestive system tumours" International Agency for Research on Cancer 2019
17 Chu KJ, "Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis" 33 : 120-126, 2010
18 Ohkubo K, "Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma" 94 : 2663-2668, 2002
19 Cescon M, "Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma" 256 : 706-712, 2012
20 Sohn JH, "Validation of the Hong Kong liver cancer staging system in determining prognosis of the north American patients following intra-arterial therapy" 15 : 746-755, 2017
21 Notarpaolo A, "Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC" 66 : 552-559, 2017
22 Park MJ, "Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusionweighted MR imaging for small hepatocellular carcinoma(≤ 2. 0 cm)in patients with hepatitis-induced liver cirrhosis" 54 : 127-136, 2013
23 Mehta N, "Validation of a risk estimation of tumor recurrence after transplant(RETREAT)score for hepatocellular carcinoma recurrence after liver transplant" 3 : 493-500, 2017
24 Kelley RK, "VP10-2021 : cabozantinib(C)plus atezolizumab(A)versus sorafenib(S)as first-line systemic treatment for advanced hepatocellular carcinoma(aHCC) : results from the randomized phase III COSMIC-312 trial" 33 : 114-116, 2022
25 Oliver SE, "Use of the Janssen(Johnson & Johnson)COVID-19 vaccine : updated interim recommendations from the Advisory Committee on Immunization Practices-United States, December 2021" 71 : 90-95, 2022
26 Khalid SK, "Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis" 7 : 994-999, 2009
27 Rossi S, "Use of over-the-counter analgesics in patients with chronic liver disease : physicians’ recommendations" 31 : 261-270, 2008
28 Gargano JW, "Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients : update from the Advisory Committee on Immunization Practices-United States, June 2021" 70 : 977-982, 2021
29 Evans TRJ, "Urine protein : creatinine ratio vs 24-hour urine protein for proteinuria management : analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma" 121 : 218-221, 2019
30 Cheng AL, "Updated efficacy and safety data from IMbrave150 : atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma" 76 : 862-873, 2022
31 Lee MW, "Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm : emphasis on association of local tumor progression and overall survival" 30 : 2391-2400, 2020
32 Alcorn JB, "United Network for Organ Sharing. Changes to OPTN bylaws and policies from actions at November board of directors meeting" United Network for Organ Sharing 2016
33 Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy" 65 : 719-726, 2016
34 Trinchet JC, "Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis : a randomized trial comparing 3-and 6-month periodicities" 54 : 1987-1997, 2011
35 Miyayama S, "Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil" 18 : 365-376, 2007
36 Jannin A, "Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders" 141 : 23-35, 2019
37 Vilana R, "Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma" 16 : 353-357, 1992
38 Yoon JS, "Tumor marker-based definition of the transarterial chemoembolization-refractoriness in intermediate-stage hepatocellular carcinoma: a multi-cohort study" 11 : 1721-, 2019
39 Llovet JM, "Trial design and endpoints in hepatocellular carcinoma : AASLD consensus conference" 73 (73): 158-191, 2021
40 Bargellini I, "Trends in utilization of transarterial treatments for hepatocellular carcinoma : results of a survey by the Italian Society of Interventional Radiology" 37 : 438-444, 2014
41 Hyder O, "Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma" 17 : 1774-1783, 2013
42 Arora A, "Treatment response evaluation and follow-up in hepatocellular carcinoma" 4 (4): S126-S129, 2014
43 Nishikawa H, "Treatment for hepatocellular carcinoma in elderly patients : a literature review" 4 : 635-643, 2013
44 Pugh RN, "Transection of the oesophagus for bleeding oesophageal varices" 60 : 646-649, 1973
45 Huo YR, "Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma : a systematic review and meta-analysis" 1 : 756-765, 2015
46 De Luna W, "Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation" 9 : 1158-1168, 2009
47 Ikeda M, "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma : a phase III randomized trial" 53 : 281-290, 2018
48 Si T, "Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma : a meta-analysis" 32 : 1286-1294, 2017
49 Choi JW, "Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus" 27 : 1448-1458, 2017
50 Bargellini I, "Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment : a prospective cohort study" 81 : 1173-1178, 2012
51 Silva JP, "Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis" 19 : 659-666, 2017
52 Luo J, "Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis : a prospective comparative study" 18 : 413-420, 2011
53 Cheng YC, "Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation" 19 : 309-316, 2014
54 Xue TC, "Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus : a metaanalysis" 13 : 60-, 2013
55 Vogl TJ, "Transarterial chemoembolization for hepatocellular carcinoma : volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center" 214 : 349-357, 2000
56 Kudo M, "Transarterial chemoembolization failure/refractoriness : JSH-LCSGJ criteria 2014 update" 87 (87): 22-31, 2014
57 Niu ZJ, "Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus : using a new classification" 29 : 2992-2997, 2012
58 Chung GE, "Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival" 258 : 627-634, 2011
59 Lesurtel M, "Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma : an evidence-based analysis" 6 : 2644-2650, 2006
60 Rimassa L, "Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma(METIV-HCC) : a final analysis of a phase 3, randomised, placebo-controlled study" 19 : 682-693, 2018
61 Yi NJ, "Three-quarters of right liver donors experienced postoperative complications" 13 : 797-806, 2007
62 Kim TH, "Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable" 29 : 568-575, 2006
63 Hsu HC, "Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma" 80 : 38-42, 2007
64 Kim DY, "Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma" 103 : 2419-2246, 2005
65 Kulik L, "Therapies for patients with hepatocellular carcinoma awaiting liver transplantation : a systematic review and meta-analysis" 67 : 381-400, 2018
66 Lee HS, "Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area : a prospective cohort study" 20 : 4459-4465, 2002
67 Hiraoka A, "Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma" 9 : 133-138, 2020
68 차동익 ; 이민우 ; 임현철 ; 최동일 ; 김영선 ; 임효근, "Therapeutic Efficacy and Safety of Percutaneous Ethanol Injection with or without Combined Radiofrequency Ablation for Hepatocellular Carcinomas in High Risk Locations" 대한영상의학회 14 (14): 240-247, 2013
69 Chiu J, "The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis : a retrospective analysis of efficacy, safety, and survival benefits" 118 : 5293-5301, 2012
70 Benson GD, "The therapeutic use of acetaminophen in patients with liver disease" 12 : 133-141, 2005
71 Makuuchi M, "The surgical approach to HCC : our progress and results in Japan" 10 (10): S46-S52, 2004
72 Upton AC, "The state of the art in the 1990’s: NCRP report No. 136 on the scientific bases for linearity in the dose-response relationship for ionizing radiation" 85 : 15-22, 2003
73 Lee HS, "The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study" 79 : 2087-2094, 1997
74 Bush DA, "The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma : a phase 2 prospective trial" 117 : 3053-3059, 2011
75 Dulku G, "The role of imaging in the surveillance and diagnosis of hepatocellular cancer" 61 : 171-179, 2017
76 Pung L, "The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma : a systematic review and meta-analysis" 28 : 334-341, 2017
77 He W, "The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients : a propensity score matching analysis" 15 : 263-, 2015
78 Roh YN, "The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation" 28 : 141-148, 2014
79 Jia W, "The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy" 16 : 655-670, 2019
80 Choi JY, "The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus" 23 : 545-551, 2017
81 Fennell ML, "The organization of multidisciplinary care teams : modeling internal and external influences on cancer care quality" 2010 : 72-80, 2010
82 Hasselström J, "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis" 29 : 289-297, 1990
83 McShane C, "The mRNA COVID-19 vaccine-a rare trigger of autoimmune hepatitis?" 75 : 1252-1254, 2021
84 Cho JY, "The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma" 34 : 795-801, 2014
85 Jeong SW, "The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma" 8 : 164-171, 2012
86 Lee JH, "The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma" 89 : 48-55, 2021
87 Pang Q, "The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma : a meta-analysis" 10 : 4645-4656, 2017
88 Chen XX, "The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection : a systematic review and meta-analysis" 10 : 5363-5375, 2017
89 Kuffner EK, "The effect of acetaminophen(four grams a day for three consecutive days)on hepatic tests in alcoholic patients--a multicenter randomized study" 5 : 13-, 2007
90 Kierans AS, "The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm : a meta-analysis" 278 : 82-94, 2016
91 Sangiovanni A, "The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis" 59 : 638-644, 2010
92 Hartke J, "The diagnosis and treatment of hepatocellular carcinoma" 34 : 153-159, 2017
93 Sieghart W, "The ART of decision making : retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma" 57 : 2261-2273, 2013
94 김인규 ; Xu-Guang Hu ; 왕희정 ; 김봉완 ; 홍성연 ; Xue-Yin Shen, "The 7th/8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma" 연세대학교의과대학 60 (60): 140-147, 2019
95 Choi J, "Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection" 73 : 661-673, 2021
96 Li M, "Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B : a critical systematic review and meta-analysis" 14 : 105-114, 2020
97 Kim YS, "Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma : analysis of prognostic factors" 58 : 89-97, 2013
98 Rimassa L, "Systemic treatment of HCC in special populations" 74 : 931-943, 2021
99 Thomas MB, "Systemic therapy for hepatocellular carcinoma" 14 : 123-127, 2008
100 Sonbol MB, "Systemic therapy and sequencing options in advanced hepatocellular carcinoma : a systematic review and network meta-analysis" 6 : e204930-, 2020
101 Tan RZH, "Systematic review with meta-analysis : the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma" 54 : 356-367, 2021
102 Saraiya N, "Systematic review with meta-analysis : recurrence of hepatocellular carcinoma following direct-acting antiviral therapy" 48 : 127-137, 2018
103 Wang HL, "Systematic review of treatment strategy for recurrent hepatocellular carcinoma: salvage liver transplantation or curative locoregional therapy" 98 : e14498-, 2019
104 Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma : chemoembolization improves survival" 37 : 429-442, 2003
105 Cho YK, "Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies" 49 : 453-459, 2009
106 Shen A, "Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm" 28 : 793-800, 2013
107 Chan DL, "Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma" 29 : 31-41, 2014
108 Suh KS, "Systematic hepatectomy for small hepatocellular carcinoma in Korea" 12 : 365-370, 2005
109 Park Hana ; 신승각 ; 주이진 ; Song Do Seon ; Jang Jeong Won ; Park Joong-Won, "Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer" 거트앤리버 소화기연관학회협의회 14 (14): 792-807, 2020
110 Ryu E, "Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma" 33 : 3-10, 2010
111 Park SJ, "Switching monopolar no-touch radiofrequency ablation using octopus electrodes for small hepatocellular carcinoma : a randomized clinical trial" 10 : 72-81, 2021
112 Lee JH, "Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma : an extended 5-year follow-up" 68 : 23-32, 2019
113 Livraghi T, "Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis : is resection still the treatment of choice?" 47 : 82-89, 2008
114 이정민 ; 장병국 ; 최왕용 ; 정우진 ; 황재석 ; 강구정 ; 김영환 ; Anil Kumar Chauhan ; 박수영 ; 탁원영 ; 권영오 ; 김병석 ; 이창형 ; 이유진 ; 최세명, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis" 대한간학회 22 (22): 160-167, 2016
115 Sakoda M, "Survival benefits of small anatomical resection of the liver for patients with hepatocellular carcinoma and impaired liver function, based on new-era imaging studies" 7 : 1029-1036, 2016
116 Kokudo T, "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion" 65 : 938-943, 2016
117 Kudo M, "Survival analysis over 28 years of 173, 378 patients with hepatocellular carcinoma in Japan" 5 : 190-197, 2016
118 Lee EC, "Survival analysis after liver resection for hepatocellular carcinoma : a consecutive cohort of 1002 patients" 32 : 1055-1063, 2017
119 Sangro B, "Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages : a European evaluation" 54 : 868-878, 2011
120 Iwazawa J, "Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma" 81 : 3985-3992, 2012
121 Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a meta-analysis" 154 : 1706-1718.e1, 2018
122 Pocha C, "Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography--a randomised study" 38 : 303-312, 2013
123 Kudo M, "Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the liver cancer study group of Japan : 2014 update" 87 (87): 7-21, 2017
124 Lee HS, "Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy" 21 : 3646-3653, 2014
125 Kwon JH, "Surgical outcomes of spontaneously ruptured hepatocellular carcinoma" 25 : 941-953, 2021
126 Moon DB, "Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus : a Korean multicenter study" 37 : 443-451, 2013
127 Kim DS, "Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus : a Korea-Japan multicenter study" 271 : 913-921, 2020
128 Kim SJ, "Surgical outcome of right liver donors in living donor liver transplantation : single-center experience with 500 cases" 16 : 1160-1170, 2012
129 Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines" 56 : 886-892, 2012
130 Cheng AL, "Sunitinib versus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial" 31 : 4067-4075, 2013
131 Choi SH, "Subtraction images of gadoxetic acid-enhanced MRI : effect on the diagnostic performance for focal hepatic lesions in patients at risk for hepatocellular carcinoma" 209 : 584-591, 2017
132 Gabr A, "Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation" 72 : 1151-1158, 2020
133 Seo Hee Choi ; 성진실, "Strategic application of radiotherapy for hepatocellular carcinoma" 대한간학회 24 (24): 114-134, 2018
134 Katz AW, "Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma : clinical outcome and pathologic correlation" 83 : 895-900, 2012
135 Sapisochin G, "Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis" 67 : 92-99, 2017
136 Sanuki N, "Stereotactic body radiotherapy for small hepatocellular carcinoma : a retrospective outcome analysis in 185patients" 53 : 399-404, 2014
137 Andolino DL, "Stereotactic body radiotherapy for primary hepatocellular carcinoma" 81 : e447-e453, 2011
138 Weiner AA, "Stereotactic body radiotherapy for primary hepatic malignancies-report of a phase I/II institutional study" 121 : 79-85, 2016
139 Beaton L, "Stereotactic body radiotherapy for large unresectable hepatocellular carcinomas-a single institution phase II study" 32 : 423-432, 2020
140 Kim N, "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" 73 : 121-129, 2020
141 Ueno M, "Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma : a propensity-score matching analysis of their impact on liver function and clinical outcomes" 12 : 2334-2344, 2021
142 Huang WY, "Stereotactic body radiation therapy in recurrent hepatocellular carcinoma" 84 : 355-361, 2012
143 Sang Min Yoon ; So Yeon Kim ; Young-Suk Lim ; Kang Mo Kim ; Ju Hyun Shim ; Danbi Lee ; Jihyun An ; Jinhong Jung ; Jong Hoon Kim ; Han Chu Lee, "Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial" 대한간학회 26 (26): 506-515, 2020
144 Honda Y, "Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma" 28 : 530-536, 2013
145 Yoon SM, "Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma" 8 : e79854-, 2013
146 Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis" 144 : 323-332, 2013
147 Choi J, "Statins and metformin for chemoprevention of hepatocellular carcinoma" 8 : 48-52, 2016
148 Cho Y, "Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients" 9 : 1467-, 2019
149 Islam MM, "Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies" 12 : 671-, 2020
150 Goh MJ, "Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B" 71 : 2023-2032, 2020
151 Kim G, "Statin use and the risk of hepatocellular carcinoma in patients at high risk : a nationwide nested case-control study" 68 : 476-484, 2018
152 Li X, "Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis" 40 : 20200232-, 2020
153 Tran KT, "Statin use and risk of liver cancer : evidence from two population-based studies" 146 : 1250-1260, 2020
154 Hyung Soon Lee ; 최기홍 ; 최진섭 ; 한광협 ; 안상훈 ; 김도영 ; 박준용 ; 김승업 ; 김성훈 ; 윤동섭 ; Jae Keun Kim ; Jong Won Choi ; Soon Sun Kim ; Hana Park, "Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea" 대한외과학회 96 (96): 275-282, 2019
155 Wu JJ, "Spontaneous rupture of hepatocellular carcinoma : optimal timing of partial hepatectomy" 45 : 1887-1894, 2019
156 Park JW, "Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma : the phase III STAH trial" 70 : 684-691, 2019
157 Ogasawara S, "Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma : safety, efficacy and prognostic factors" 33 : 729-739, 2015
158 Kudo M, "Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS) : a randomised, open label, phase 3 trial" 3 : 424-432, 2018
159 He M, "Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion : a randomized clinical trial" 5 : 953-960, 2019
160 Ikeda M, "Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma : randomized phase II trial" 27 : 2090-2096, 2016
161 Zheng K, "Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis : a randomized trial" 303 : 455-464, 2022
162 Lencioni R, "Sorafenib or placebo plus TACE with doxorubicineluting beads for intermediate stage HCC : the SPACE trial" 64 : 1090-1098, 2016
163 Pressiani T, "Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma : a prospective feasibility analysis" 24 : 406-411, 2013
164 Meyer T, "Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma(TACE 2) : a randomised placebocontrolled, double-blind, phase 3 trial" 2 : 565-575, 2017
165 Llovet JM, "Sorafenib in advanced hepatocellular carcinoma" 359 : 378-390, 2008
166 Kim JE, "Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function" 68 : 1285-1290, 2011
167 김영애 ; 이예린 ; 박정주 ; 오인환 ; 김호섭 ; 윤석준 ; 박기호, "Socioeconomic Burden of Cancer in Korea from 2011 to 2015" 대한암학회 52 (52): 896-906, 2020
168 Patel IJ, "Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part II : recommendations : endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe" 30 : 1168-1184.e1, 2019
169 Yu MH, "Small(≤1-cm)hepatocellular carcinoma : diagnostic performance and imaging features at gadoxetic acidenhanced MR imaging" 271 : 748-760, 2014
170 Yang HJ, "Small single-nodule hepatocellular carcinoma : comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting" 271 : 909-918, 2014
171 Park MJ, "Small hepatocellular carcinomas : improved sensitivity by combining gadoxetic acid-enhanced and diffusionweighted MR imaging patterns" 264 : 761-770, 2012
172 Lencioni RA, "Small hepatocellular carcinoma in cirrhosis : randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection" 228 : 235-240, 2003
173 Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization" 188 : 79-83, 1993
174 Kang TW, "Small hepatocellular carcinoma : radiofrequency ablation versus nonanatomic resection--propensity score analyses of long-term outcomes" 275 : 908-919, 2015
175 Shibata T, "Small hepatocellular carcinoma : is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?" 252 : 905-913, 2009
176 Liang W, "Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma : a meta-analysis" 18 : 62-69, 2012
177 Yan X, "Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma : a systematic review and meta-analysis" 28 : 1063-1077, 2022
178 Jang JW, "Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases" 74 : 412-418, 2009
179 Takada Y, "Significance of preoperative fluorodeoxyglucosepositron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients : a Japanese multicenter study" 24 : 49-57, 2017
180 Waissengrin B, "Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors" 22 : 581-583, 2021
181 Kim HY, "Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma" 27 : 1051-1056, 2012
182 Belghiti J, "Seven hundred forty-seven hepatectomies in the 1990s : an update to evaluate the actual risk of liver resection" 191 : 38-46, 2000
183 Lee JH, "Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria" 263 : 842-850, 2016
184 Santi V, "Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival" 53 : 291-297, 2010
185 BenguerfiS, "Selective internal radiation therapy in older patients with hepatocellular carcinoma : a retrospective analysis" 34 : 417-421, 2022
186 Tsujita E, "Selective hepatic vascular exclusion for the hepatic resection of HCC" 54 : 527-530, 2007
187 Minagawa M, "Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma" 238 : 703-710, 2003
188 Stigliano R, "Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC" 33 : 437-447, 2007
189 Chen JG, "Screening for liver cancer : results of a randomised controlled trial in Qidong, China" 10 : 204-209, 2003
190 유정일 ; 박희철 ; 임도훈 ; 김철진 ; Dongryul Oh ; 유병철 ; 백승운 ; 고광철 ; 이준혁, "Scheduled Interval Trans-Catheter Arterial Chemoembolization Followed by Radiation Therapy in Patients with Unresectable Hepatocellular Carcinoma" 대한의학회 27 (27): 736-743, 2012
191 Bae SH, "Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma" 82 : e603-e607, 2012
192 Imai K, "Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy" 44 : E335-E345, 2014
193 Yoon YI, "Salvage living donor liver transplantation versus repeat liver resection for patients with recurrent hepatocellular carcinoma and Child-Pugh class A liver cirrhosis : a propensity score-matched comparison" 22 : 165-176, 2022
194 Kim JH, "Saftey and long-term outcome following major hepatectomy for epatocellular carcinoma combined with compensated liver cirrhosis" 70 : 445-450, 2006
195 Kelley RK, "Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma : randomized expansion of a phase I/II study" 39 : 2991-3001, 2021
196 Biondani P, "Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient" 29 : 286-287, 2018
197 Zhong L, "Safety of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma" 11 : 686621-, 2021
198 Georgiades CS, "Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis" 16 : 1653-1659, 2005
199 Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine" 383 : 2603-2615, 2020
200 Hollebecque A, "Safety and efficacy of sorafenib in hepatocellular carcinoma : the impact of the Child-Pugh score" 34 : 1193-1201, 2011
201 Waghray A, "Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation" 27 : 555-561, 2013
202 Zhou YM, "Safety and efficacy of partial hepatectomy for huge (≥10 cm) hepatocellular carcinoma: a systematic review" 17 : RA76-RA83, 2011
203 Ogushi K, "Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice : a multicenter analysis" 13 : 385-396, 2020
204 Yoshida H, "Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma" 2 : 89-94, 2008
205 Deipolyi AR, "Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma" 26 : 516-522, 2015
206 Chow PKH, "SIRveNIB : selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma" 36 : 1913-1921, 2018
207 Zhu AX, "SEARCH : a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma" 33 : 559-566, 2015
208 Riaz IB, "Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment : a metaanalysis of randomized controlled trials" 12 : 170-, 2012
209 Gish RG, "Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma" 6 : 173-185, 2012
210 Mannina EM, "Role of stereotactic body radiation therapy before orthotopic liver transplantation : retrospective evaluation of pathologic response and outcomes" 97 : 931-938, 2017
211 Chang WI, "Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib" 37 : 387-394, 2022
212 Xu X, "Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma" 29 : 1273-1278, 2014
213 Jung SM, "Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases" 27 : 684-689, 2012
214 Chen VL, "Role of biomarkers and biopsy in hepatocellular carcinoma" 24 : 577-590, 2020
215 Colombo M, "Role of antiviral treatment for HCC prevention" 28 : 771-781, 2014
216 Pesi B, "Robotic versus open liver resection in hepatocarcinoma : surgical and oncological outcomes" 31 : 468-474, 2021
217 Kim DY, "Risk-adapted simultaneous integrated boost-proton beam therapy(SIB-PBT)for advanced hepatocellular carcinoma with tumour vascular thrombosis" 122 : 122-129, 2017
218 Kim BK, "Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization : development of a prediction model" 36 : 92-99, 2016
219 Farges O, "Risk of major liver resection in patients with underlying chronic liver disease : a reappraisal" 229 : 210-215, 1999
220 Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study" 5 : 30-36, 2019
221 Park JW, "Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBVrelated hepatocellular carcinoma : report of a prospective study" 100 : 2194-2200, 2005
222 Lee PC, "Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma" 8 : e001072-, 2020
223 Papatheodoridi M, "Risk of HBV reactivation during therapies for HCC : a systematic review" 75 : 1257-1274, 2022
224 Jang JW, "Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma" 16 : 969-977, 2011
225 Adachi E, "Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma" 108 : 768-775, 1995
226 Wu JC, "Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma" 51 : 890-897, 2009
227 Li SH, "Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection" 14 : 4759-4763, 2013
228 Imamura H, "Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy" 38 : 200-207, 2003
229 Li J, "Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma : a casecontrol study" 20 : 9121-9127, 2014
230 Fujiwara N, "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine" 68 : 526-549, 2018
231 Kim N, "Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma" 131 : 81-87, 2019
232 Adhoute X, "Retreatment with TACE : the ABCR SCORE, an aid to the decision-making process" 62 : 855-862, 2015
233 Sasaki R, "Response to lenvatinib is associated with optimal relativedose intensity in hepatocellular carcinoma: experience in clinical settings" 11 : 1769-, 2019
234 Mei J, "Resection vs. sorafenib for hepatocellular carcinoma with macroscopic vascular invasion : a real world, propensity score matched analytic study" 10 : 573-, 2020
235 Zhang ZY, "Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: a systematic review and meta-analysis" 98 : e18362-, 2019
236 Sotiropoulos GC, "Resectability of hepatocellular carcinoma : evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature" 53 : 322-329, 2006
237 Miller AB, "Reporting results of cancer treatment" 47 : 207-214, 1981
238 Pomfret EA, "Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States" 16 : 262-278, 2010
239 Rossi S, "Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas : a long-term cohort study" 53 : 136-147, 2011
240 Okuwaki Y, "Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma" 104 : 2747-2753, 2009
241 Kubo S, "Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C" 90 : 1076-1080, 1999
242 Wilhelm SM, "Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity" 129 : 245-255, 2011
243 Choi WM, "Regorafenib versus nivolumab after sorafenib failure : realworld data in patients with hepatocellular carcinoma" 4 : 1073-1086, 2020
244 Abou-Elkacem L, "Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model" 12 : 1322-1331, 2013
245 Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3trial" 389 : 56-66, 2017
246 Iavarone M, "Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation : a retrospective study" 27 : 1767-1778, 2021
247 Wang Y, "Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing : a cohort study in Beijing, China" 5 : e002794-, 2020
248 Peng ZW, "Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone : a prospective randomized trial" 262 : 689-700, 2012
249 Kim YS, "Recurrence of hepatocellular carcinoma after liver transplantation : patterns and prognostic factors based on clinical and radiologic features" 189 : 352-358, 2007
250 Roayaie S, "Recurrence of hepatocellular carcinoma after liver transplant : patterns and prognosis" 10 : 534-540, 2004
251 Tabrizian P, "Recurrence of hepatocellular cancer after resection : patterns, treatments, and prognosis" 261 : 947-955, 2015
252 Hung IF, "Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection" 103 : 1663-1673, 2008
253 Clavien PA, "Recommendations for liver transplantation for hepatocellular carcinoma : an international consensus conference report" 13 : e11-e22, 2012
254 Siegler M, "Recipient deaths during donor surgery : a new ethical problem in living donor liver transplantation(LDLT)" 12 : 358-360, 2006
255 Chwistek M, "Recent advances in understanding and managing cancer pain" 6 : 945-, 2017
256 김종만 ; Jinsoo Rhu ; Sang Yun Ha ; Gyu-Seong Choi ; Choon Hyuck David Kwon ; Gaabsoo Kim ; Jae-Won Joh, "Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older" 대한외과학회 101 (101): 257-265, 2021
257 Cheon J, "Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma : a multicenter retrospective analysis" 9 : 613-624, 2020
258 Ahn SJ, "Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma" 66 : 347-354, 2017
259 Kubo S, "Reactivation of viral replication after liver resection in patients infected with hepatitis B virus" 233 : 139-145, 2001
260 Jang JW, "Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma" 10 : e0122041-, 2015
261 Choi JH, "Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis" 82 : 469-478, 2018
262 Kondo M, "Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma : SCOOP-2 trial" 19 : 954-, 2019
263 Qin S, "Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia" 31 : 3501-3508, 2013
264 Llovet JM, "Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival" 70 : 1262-1277, 2019
265 Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma" 35 : 1164-1171, 2002
266 Ren Z, "Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma" 33 : 894-900, 2015
267 Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma" 130 : 417-422, 2004
268 Pitton MB, "Randomized comparison of selective internal radiotherapy(SIRT)versus drug-eluting bead transarterial chemoembolization(DEB-TACE)for the treatment of hepatocellular carcinoma" 38 : 352-360, 2015
269 Ng KKC, "Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma" 104 : 1775-1784, 2017
270 Bush DA, "Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma : results of an interim analysis" 95 : 477-482, 2016
271 Kudo M, "Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial" 69 : 1492-1501, 2020
272 Golfieri R, "Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma" 111 : 255-264, 2014
273 Lin SM, "Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less" 54 : 1151-1156, 2005
274 Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicentre, phase 3 trial" 16 : 859-870, 2015
275 Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, doubleblind, placebo-controlled, phase 3 trial" 20 : 282-296, 2019
276 Yoon SM, "Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein : long-term patient outcomes" 82 : 2004-2011, 2012
277 Tanaka Y, "Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels : efficacy and outcomes" 29 : 352-357, 2014
278 Seong J, "Radiotherapy for painful bone metastases from hepatocellular carcinoma" 25 : 261-265, 2005
279 Yamashita H, "Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma : retrospective study" 22 : 523-527, 2007
280 Hara K, "Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation : a propensity score analysis" 69 : 2533-2545, 2019
281 Jung J, "Radiotherapy for adrenal metastasis from hepatocellular carcinoma : a multi-institutional retrospective study(KROG 13-05)" 11 : e0152642-, 2016
282 Im JH, "Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area" 37 : 90-100, 2017
283 Sang Min Yoon ; Jong Hoon Kim ; Eun Kyung Choi ; Seung Do Ahn ; Sang-wook Lee ; Byong Yong Yi ; Young Wha Chung ; Young Sang Lee ; Dong Jin Seo, "Radioresponse of Hepatocellular Carcinoma-Treatment of Lymph Node Metastasis" 대한암학회 36 (36): 79-84, 2004
284 Joo I, "Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI : a multicenter study" 296 : 335-345, 2020
285 Peng ZW, "Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma : a prospective randomized trial" 31 : 426-432, 2013
286 Lee S, "Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma : propensity score analyses of long-term outcomes" 69 : 70-78, 2018
287 Jeong Y, "Radiofrequency ablation versus stereotactic body radiation therapy for small(≤ 3 cm)hepatocellular carcinoma : a retrospective comparison analysis" 36 : 1962-1970, 2021
288 Yang B, "Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma : a meta-analysis of randomized controlled trials" 13 : 96-, 2015
289 Qi X, "Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma : a meta-analysis of randomized controlled trials" 48 : 450-457, 2014
290 Brunello F, "Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma : a randomized controlled trial" 43 : 727-735, 2008
291 Lu Z, "Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma : a metaanalysis of randomized-controlled trials" 25 : 187-194, 2013
292 Mazzaferro V, "Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation : a prospective study" 240 : 900-909, 2004
293 Lee DH, "Radiofrequency ablation of hepatocellular carcinoma as first-line treatment : long-term results and prognostic factors in 162 patients with cirrhosis" 270 : 900-909, 2014
294 Lee MW, "Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation : a 10-year intention-to-treat analysis" 65 : 1979-1990, 2017
295 Lin SM, "Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm" 127 : 1714-1723, 2004
296 Kashima M, "Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma" 194 : 536-541, 2010
297 Shiina S, "Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors" 107 : 569-577, 2012
298 Kim GA, "Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas" 103 : 126-135, 2016
299 Currie BM, "Radioembolization-induced chronic hepatotoxicity : a single-center cohort analysis" 30 : 1915-1923, 2019
300 Hilgard P, "Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma : European experience on safety and long-term survival" 52 : 1741-1749, 2010
301 Salem R, "Radioembolization with 90Yttrium microspheres : a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1 : technical and methodologic considerations" 17 : 1251-1278, 2006
302 Casadei Gardini A, "Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma : a meta-analysis of randomized trials" 11 : 7315-7321, 2018
303 Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres : a comprehensive report of long-term outcomes" 138 : 52-64, 2010
304 Pan CC, "Radiation-associated liver injury" 76 : S94-S100, 2010
305 Rades D, "Radiation therapy for metastatic spinal cord compression in patients with hepatocellular carcinoma" 29 : 749-752, 2015
306 Park YJ, "Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma" 41 : 1099-1106, 2006
307 Sakaguchi M, "Radiation therapy and palliative care prolongs the survival of hepatocellular carcinoma patients with bone metastases" 55 : 1077-1083, 2016
308 Yoon YI, "Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis : a propensity score matched analysis" 265 : 856-863, 2017
309 Chiou VL, "Pseudoprogression and immune-related response in solid tumors" 33 : 3541-3543, 2015
310 Sugahara S, "Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis" 185 : 782-788, 2009
311 Nakayama H, "Proton beam therapy for hepatocellular carcinoma : the University of Tsukuba experience" 115 : 5499-5506, 2009
312 Tremosini S, "Prospective validation of an immunohistochemical panel(glypican 3, heat shock protein 70 and glutamine synthetase)in liver biopsies for diagnosis of very early hepatocellular carcinoma" 61 : 1481-1487, 2012
313 Yamada K, "Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma" 57 : 113-119, 2003
314 Ikeda M, "Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma : an Asian cooperative study between Japan and Korea" 24 : 490-500, 2013
315 Wong TC, "Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant" 74 : 2580-2594, 2021
316 Lammer J, "Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study" 33 : 41-52, 2010
317 Chong CCN, "Prospective double-blinded randomized controlled trial of microwave versus radiofrequency ablation for hepatocellular carcinoma(McRFA trial)" 22 : 1121-1127, 2020
318 Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients" 131 : 461-469, 2006
319 Khan KN, "Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection" 32 : 269-278, 2000
320 Lee Myungsu ; Chung Jin Wook ; Lee Kwang-Hun ; Won Jong Yun ; Chun Ho Jong ; Lee Han Chu ; Kim Jin Hyoung ; Lee In Joon ; 허세범 ; Kim Hyo-Cheol ; Kim Yoon Jun ; Kim Gyoung Min ; Joo Seung-Moon ; Oh Jung Suk, "Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis" 대한영상의학회 22 (22): 1658-1670, 2021
321 Lee SD, "Proposal of new expanded selection criteria using total tumor size and(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma : the National Cancer Center Korea criteria" 6 : 411-422, 2016
322 Nagamatsu H, "Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy" 99 : 2369-2375, 2004
323 Ishii M, "Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma" 20 : 3335-3342, 2014
324 Kasuya G, "Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma : combined analyses of 2prospective trials" 123 : 3955-3965, 2017
325 Huang Z, "Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection : a metaanalysis" 13 : e0190512-, 2018
326 Sugimachi K, "Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma" 91 : 570-574, 2011
327 Granito A, "Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib" 9 : 240-249, 2016
328 Ueno S, "Prognostic performance of the new classification of primary liver cancer of Japan(4th edition)for patients with hepatocellular carcinoma : a validation analysis" 24 : 395-403, 2002
329 Zhong FP, "Prognostic impact of surgical margin in patients with hepatocellular carcinoma:a meta-analysis" 96 : e8043-, 2017
330 Aoki T, "Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma : an analysis of 1160 cases from a nationwide survey" 259 : 532-542, 2014
331 Kim Y, "Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma : a multi-institutional retrospective study(KROG 15-02)" 8 : 94450-94461, 2017
332 Zhou L, "Prognostic factors of solitary large hepatocellular carcinoma : the importance of differentiation grade" 37 : 521-525, 2011
333 Gil-Alzugaray B, "Prognostic factors and prevention of radioembolization-induced liver disease" 57 : 1078-1087, 2013
334 유정일 ; 박희철 ; 임도훈 ; 박원 ; 유병철 ; 백승운 ; 고광철 ; 이준혁, "Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy" 대한의학회 26 (26): 1014-1022, 2011
335 Yun BY, "Prognosis of early-stage hepatocellular carcinoma:comparison between trans-arterial chemoembolization and radiofrequency ablation" 12 : 2527-, 2020
336 Mallet V, "Prognosis of French COVID-19 patients with chronic liver disease : a national retrospective cohort study for 2020" 75 : 848-855, 2021
337 Ahmed M, "Principles of and advances in percutaneous ablation" 258 : 351-369, 2011
338 Sangro B, "Prevention and treatment of complications of selective internal radiation therapy : expert guidance and systematic review" 66 : 969-982, 2017
339 Hirschfield GM, "Preventative hepatology : minimising symptoms and optimising care" 28 : 922-934, 2008
340 van den Beuken-van Everdingen MH, "Prevalence of pain in patients with cancer : a systematic review of the past 40years" 18 : 1437-1449, 2007
341 Kovalic AJ, "Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes : a systematic review and meta-analysis" 14 : 612-620, 2020
342 Kim JY, "Prevalence and management of pain by different age groups of Korean cancer patients" 30 : 393-398, 2013
343 Wu CC, "Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma : a reappraisal" 82 : 122-126, 1995
344 Bai S, "Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus-related hepatocellular carcinoma" 28 : 8174-8185, 2021
345 Jianyong L, "Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma" 7 : 41624-, 2017
346 Iavarone M, "Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation" 19 : 3176-3184, 2019
347 Nathan H, "Predictors of survival after resection of early hepatocellular carcinoma" 249 : 799-805, 2009
348 Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease : US multi-center study" 19 : 1469-1479, 2021
349 Halazun KJ, "Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria" 82S : 61-69, 2020
350 Kaibori M, "Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma" 102 : 462-468, 2010
351 Okada S, "Predictive factors for postoperative recurrence of hepatocellular carcinoma" 106 : 1618-1624, 1994
352 Choi GH, "Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma" 31 : 485-493, 2011
353 Kim SU, "Prediction of postoperative hepatic insufficiency by liver stiffness measurement(FibroScan®)before curative resection of hepatocellular carcinoma : a pilot study" 2 : 471-477, 2008
354 Nishio T, "Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma" 159 : 399-408, 2016
355 Schadde E, "Prediction of mortality after ALPPS stage-1 : an analysis of 320 patients from the international ALPPS registry" 262 : 780-785, 2015
356 Zheng J, "Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection : validation of a clinical risk score in an international cohort" 266 : 693-701, 2017
357 Bodzin AS, "Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation : impact of treatment modality and recurrence characteristics" 266 : 118-125, 2017
358 Kim JM, "Predicting hepatocellular carcinoma recurrence beyond milan criteria after liver resection for solitary hepatocellular carcinoma" 24 : 2219-2227, 2020
359 Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009" 15 : 391-423, 2009
360 Shim JH, "Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virusendemic area" 135 : 617-625, 2009
361 Maruta S, "Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma" 9 : 382-396, 2020
362 Koroki K, "Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma" 10 : 473-484, 2021
363 Reig M, "Postprogression survival of patients with advanced hepatocellular carcinoma : rationale for secondline trial design" 58 : 2023-2031, 2013
364 Miao RY, "Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma : a meta-analysis" 16 : 2931-2942, 2010
365 Chalaye J, "Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma" 69 : 336-344, 2018
366 Beppu T, "Portal vein embolization followed by right-side hemihepatectomy for hepatocellular carcinoma patients : a Japanese multi-institutional study" 222 : 1138-1148.e2, 2016
367 Capussotti L, "Portal hypertension : contraindication to liver surgery?" 30 : 992-999, 2006
368 Kolligs FT, "Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma" 35 : 1715-1721, 2015
369 DeLeon TT, "Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation : the Mayo Clinic experience" 9 : 1054-1062, 2018
370 Han KH, "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis" 113 : 995-1003, 2008
371 Soliman H, "Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases" 31 : 3980-3986, 2013
372 Kawashima M, "Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma" 23 : 1839-1846, 2005
373 Kim TH, "Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma" 10 : 542-, 2020
374 Kim JW, "Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma" 51 : 445-451, 2019
375 Furuse J, "Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma" 99 : 159-165, 2008
376 김태현 ; 박중원 ; 김연주 ; 김보현 ; 우상명 ; 문승호 ; 김상수 ; 고영환 ; 이우진 ; 박상재 ; 김주영 ; 김대용 ; 김창민, "Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma" 대한암학회 47 (47): 34-45, 2015
377 Abou-Alfa GK, "Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA" (4_suppl) : 379-, 2022
378 Takeda A, "Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation" 122 : 2041-2049, 2016
379 Kotb HI, "Pharmacokinetics of oral tramadol in patients with liver cancer" 4 : 99-104, 2008
380 Durnin C, "Pharmacokinetics of oral immediate-release hydromorphone(Dilaudid IR)in subjects with moderate hepatic impairment" 44 : 83-84, 2001
381 Tegeder I, "Pharmacokinetics of opioids in liver disease" 37 : 17-40, 1999
382 Kotb HI, "Pharmacokinetics of controlled release morphine(MST)in patients with liver carcinoma" 94 : 95-99, 2005
383 Tallgren M, "Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation" 61 : 655-661, 1997
384 Villeneuve JP, "Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects" 7 : 898-902, 1983
385 Verbeeck RK, "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction" 64 : 1147-1161, 2008
386 Bhoori S, "Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation : a proof of principle" 52 : 771-775, 2010
387 Garin E, "Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma(DOSISPHERE-01) : a randomised, multicentre, open-label phase 2 trial" 6 : 17-29, 2021
388 Kim BK, "Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection" 28 : 393-401, 2008
389 Chan SC, "Perpetuating proficiency in donor right hepatectomy for living donor liver transplantation" 37 : 65-72, 2014
390 Wada H, "Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery : a multi-center analysis" 48 : 73-79, 2018
391 Liu L, "Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma : a meta-analysis" 8 : e64261-, 2013
392 Yang Y, "Perfluorobutane contrastenhanced ultrasonography for the diagnosis of HCC: a systematic review and meta-analysis" 46 : 4619-4628, 2021
393 Giorgio A, "Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients : an Italian randomized controlled trial" 31 : 2291-2295, 2011
394 Song I, "Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites : safety and technical efficacy in 143 patients" 19 : 2630-2640, 2009
395 Yu Q, "Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials" 46 : 4467-4475, 2021
396 Livraghi T, "Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients" 69 : 925-929, 1992
397 Ebara M, "Percutaneous ethanol injection for small hepatocellular carcinoma : therapeutic efficacy based on 20-year observation" 43 : 458-464, 2005
398 Lencioni R, "Percutaneous ethanol injection for hepatocellular carcinoma : alive or dead?" 43 : 377-380, 2005
399 Kim R, "Percutaneous cryoablation for perivascular hepatocellular carcinoma : therapeutic efficacy and vascular complications" 29 : 654-662, 2019
400 Chen S, "Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining : a multicenter retrospective study" 21 : 1126-, 2021
401 Qin S, "Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEY-NOTE-394 study" (4_suppl) : 383-, 2022
402 Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial" 19 : 940-952, 2018
403 Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial" 38 : 193-202, 2020
404 Tazdait M, "Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy : comparison of RECIST 1. 1, irRECIST and iRECIST criteria" 88 : 38-47, 2018
405 Sinn DH, "Patterns and outcomes in hepatocellular carcinoma patients with portal vein invasion : a multicenter prospective cohort study" 66 : 315-324, 2021
406 Roskams T, "Pathology of early hepatocellular carcinoma : conventional and molecular diagnosis" 30 : 17-25, 2010
407 DiNorcia J, "Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma : analysis from the US multicenter HCC transplant consortium" 271 : 616-624, 2020
408 Shi M, "Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma : a prospective randomized trial" 245 : 36-43, 2007
409 Jiang W, "Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma" 29 : 197-205, 2012
410 Yeung CSY, "Palliative liver radiotherapy(RT)for symptomatic hepatocellular carcinoma(HCC)" 10 : 1254-, 2020
411 Chandok N, "Pain management in the cirrhotic patient : the clinical challenge" 85 : 451-458, 2010
412 Radner H, "Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity" 1 : CD008951-, 2012
413 Carr BI, "Pain at presentation and survival in hepatocellular carcinoma" 11 : 988-993, 2010
414 Kim DY, "PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection" 72 (72): 52-57, 2007
415 Petrelli F, "Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. A systematic review and pooled analysis" 26 : 488-496, 2014
416 Nakazawa T, "Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis : propensity score analysis" 14 : 84-, 2014
417 Gupta P, "Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC : a systematic review and Bayesian network meta-analysis" 31 : 5400-5408, 2021
418 Rho SY, "Outcomes of robotic living donor right hepatectomy from 52 consecutive cases : comparison with open and laparoscopy-assisted donor hepatectomy" 275 : e433-e442, 2022
419 Charriere B, "Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings" 115 : 330-336, 2017
420 Chapman WC, "Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation" 248 : 617-625, 2008
421 Choi JY, "Outcomes of living liver donors are worse than those of matched healthy controls" 76 : 628-638, 2022
422 Kulik LM, "Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma : results of the A2ALL cohort" 12 : 2997-3007, 2012
423 Wahl DR, "Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma" 34 : 452-459, 2016
424 Lee DH, "Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma : a multicenter clinical trial" 301 : 229-236, 2021
425 Benedetti Cacciaguerra A, "Outcome of major hepatectomy in cirrhotic patients; does surgical approach matter? A propensity score matched analysis" 2021
426 Lee DH, "Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST?" 8 : 771-887, 2021
427 Ogata F, "Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease" 93 : 92-98, 2017
428 Nagata Y, "Osseous metastases from hepatocellular carcinoma : embolization for pain control" 12 : 149-153, 1989
429 Kudo M, "Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma(ORIENTAL) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 study" 3 : 37-46, 2018
430 Lim H, "Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma : a systematic review" 113 : 123-136, 2021
431 Khalili K, "Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma : an analysis of diagnostic performance and resource utilization" 54 : 723-728, 2011
432 Dai Y, "Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma : a meta-analysis" 14 : 101238-, 2021
433 Smith HS, "Opioid metabolism" 84 : 613-624, 2009
434 Friberg S, "On the growth rates of human malignant tumors : implications for medical decision making" 65 : 284-297, 1997
435 Marrero JA, "Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups : the GIDEON study" 65 : 1140-1147, 2016
436 Lencioni R, "Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC" 66 : 1166-1172, 2017
437 Kim JH, "Novel albumin-bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization" 63 : 1062-1071, 2018
438 Lee YC, "Nonsteroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients" 32 : 859-866, 2012
439 Sahasrabuddhe VV, "Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma" 104 : 1808-1814, 2012
440 Kim SE, "Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virusendemic area" 31 : 1468-1476, 2011
441 Joo I, "Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout?" 25 : 2859-2868, 2015
442 Shim CW, "Noncirrhotic hepatocellular carcinoma : etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area" 10 : 529-536, 2017
443 Bessone F, "Non-steroidal anti-inflammatory drugs : what is the actual risk of liver damage?" 16 : 5651-5661, 2010
444 Moctezuma-Velázquez C, "Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B" 3 : 100364-, 2021
445 Lee DH, "Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI : risk of HCC recurrence after radiofrequency ablation" 62 : 1122-1130, 2015
446 Hu H, "Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma : the evidence from ultrasound data" 28 : 877-885, 2018
447 Suh Yun Seok ; Choi Jae Won ; Yoon Jeong Hee ; Lee Dong Ho ; Kim Yoon Jun ; Lee Jeong-Hoon ; Yu Su Jong ; Cho Eun Ju ; Yoon Jung-Hwan ; Lee Jeong Min, "No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study" 대한영상의학회 22 (22): 1974-1984, 2021
448 Peng T, "No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma : a propensity score matching analysis" 20 : 719-728, 2018
449 Yau T, "Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459) : a randomised, multicentre, open-label, phase 3 trial" 23 : 77-90, 2022
450 El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1/2 dose escalation and expansion trial" 389 : 2492-2502, 2017
451 Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)" 45 : 228-247, 2009
452 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 : 205-216, 2000
453 Li MF, "Network metaanalysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion" 14 : 1157-1168, 2018
454 Wei X, "Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus : a randomized, open-label, multicenter controlled study" 37 : 2141-2151, 2019
455 Ishizawa T, "Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma" 134 : 1908-1916, 2008
456 Silva MA, "Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer : a systematic review and meta-analysis" 57 : 1592-1596, 2008
457 Barbara L, "Natural history of small untreated hepatocellular carcinoma in cirrhosis : a multivariate analysis of prognostic factors of tumor growth rate and patient survival" 16 : 132-137, 1992
458 Hollebecque A, "Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation" 33 : 361-369, 2009
459 D’Amico G, "Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies" 44 : 217-231, 2006
460 Williams RL, "Naproxen disposition in patients with alcoholic cirrhosis" 27 : 291-296, 1984
461 National Comprehensive Cancer Network (NCCN), "NCCN: cancer and COVID-19 vaccination version 7.0. Plymouth Meeting"
462 National Comprehensive Cancer Network (NCCN), "NCCN clinical practice guideline in oncology: adult cancer pain. Vol. 1"
463 Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC" 592 : 450-456, 2021
464 Yoon SH, "Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter : tumor size and cellular differentiation" 193 : W482-W489, 2009
465 Taylor C, "Multidisciplinary team working in cancer:what is the evidence?" 340 : c951-, 2010
466 Colombo M, "Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma : a European perspective" 25 : 639-651, 2013
467 Cohen GS, "Multidisciplinary management of hepatocellular carcinoma : a model for therapy" 6 : 189-195, 2013
468 Rilling WS, "Multidisciplinary management of hepatocellular carcinoma" 13 : S259-S263, 2002
469 Litton G, "Multidisciplinary cancer care with a patient and physician satisfaction focus" 6 : e35-e37, 2010
470 Sinn DH, "Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients" 14 : e0210730-, 2019
471 Urbano J, "Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma" 126 : 108966-, 2020
472 Wang C, "Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma" 61 : 1579-1590, 2015
473 Kimura T, "Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma : the STRSPH study" 51 : 461-471, 2021
474 Hong TS, "Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma" 34 : 460-468, 2016
475 Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine" 147 : 152-161, 2014
476 Calderaro J, "Molecular and histological correlations in liver cancer" 71 : 616-630, 2019
477 Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma" 30 : 52-60, 2010
478 Ruzzenente A, "Minimally invasive versus open liver resection for hepatocellular carcinoma in the setting of portal vein hypertension : results of an international multiinstitutional analysis" 27 : 3360-3371, 2020
479 Weng DS, "Minimally invasive treatment combined with cytokineinduced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas" 31 : 63-71, 2008
480 Mazzaferro V, "Milan criteria in liver transplantation for hepatocellular carcinoma : an evidence-based analysis of 15years of experience" 17 (17): S44-S57, 2011
481 Morimoto M, "Midterm outcomes in patients with intermediatesized hepatocellular carcinoma : a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization" 116 : 5452-5460, 2010
482 Imai K, "Microvascular invasion in small-sized hepatocellular carcinoma : significance for outcomes following hepatectomy and radiofrequency ablation" 38 : 1053-1060, 2018
483 Shindoh J, "Microvascular invasion and a size cutoffvalue of 2 cm predict long-term oncological outcome in multiple hepatocellular carcinoma : reappraisal of the American joint committee on cancer staging system and validation using the surveillance, epidemiology, and endresults database" 9 : 156-166, 2020
484 Finkelstein SD, "Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma" 37 : 871-879, 2003
485 Brandi G, "Metronomic capecitabine in advanced hepatocellular carcinoma patients : a phase II study" 18 : 1256-1257, 2013
486 Chen HP, "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner : population-based and in vitro studies" 62 : 606-615, 2013
487 Khajeh E, "Meta-analysis of the effect of the pringle maneuver on long-term oncological outcomes following liver resection" 11 : 3279-, 2021
488 Zhou Y, "Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma" 10 : 78-, 2010
489 Ni JY, "Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma" 19 : 3872-3882, 2013
490 Erridge S, "Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma" 104 : 1433-1442, 2017
491 Wong JS, "Meta-analysis : the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma" 33 : 1104-1112, 2011
492 Singal A, "Meta-analysis : surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis" 30 : 37-47, 2009
493 Singal AK, "Meta-analysis : interferon improves outcomes following ablation or resection of hepatocellular carcinoma" 32 : 851-858, 2010
494 Park CJ, "Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC" 28 : 1476-1484, 2018
495 Brose MS, "Management of sorafenib-related adverse events: a clinician’s perspective" 41 (41): S1-S16, 2014
496 Majumdar A, "Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis" 3 : CD011650-, 2017
497 Kudo M, "Management of hepatocellular carcinoma in Japan : JSH consensus statements and recommendations 2021 update" 10 : 181-223, 2021
498 Bruix J, "Management of hepatocellular carcinoma : an update" 53 : 1020-1022, 2011
499 Bruix J, "Management of hepatocellular carcinoma" 42 : 1208-1236, 2005
500 Capussotti L, "Major liver resections for hepatocellular carcinoma on cirrhosis : early and long-term outcomes" 10 (10): S64-S68, 2004
501 Rhim H, "Major complications after radio-frequency thermal ablation of hepatic tumors : spectrum of imaging findings" 23 : 123-134, 2003
502 Min JH, "Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography" 18 : 2091-2100.e7, 2020
503 Kim YY, "MRI ancillary features for LI-RADS category 3 and 4 observations : improved categorization to indicate the risk of hepatic malignancy" 215 : 1354-1362, 2020
504 Pregler B, "Low tube voltage liver MDCT with sinogram-affirmed iterative reconstructions for the detection of hepatocellular carcinoma" 7 : 9460-, 2017
505 Van Wettere M, "Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with budd-chiari syndrome" 70 : 1123-1132, 2019
506 Xia Y, "Longterm effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma : a randomized clinical trial" 6 : 255-263, 2020
507 Cheung TT, "Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis : a single-center experience" 257 : 506-511, 2013
508 Roayaie S, "Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters" 235 : 533-539, 2002
509 Kim J, "Long-term outcomes of transarterial radioembolization for large single hepatocellular carcinoma : a comparison to resection" 63 : 1215-1222, 2022
510 Fukuda K, "Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma" 108 : 497-503, 2017
511 Hwang S, "Long-term outcome after resection of huge hepatocellular carcinoma ≥ 10 cm : single-institution experience with 471patients" 39 : 2519-2528, 2015
512 Ho MH, "Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma" 18 : 3632-3639, 2011
513 Lencioni R, "Loco-regional treatment of hepatocellular carcinoma" 52 : 762-773, 2010
514 Ishii H, "Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection" 77 : 1792-1796, 1996
515 Xie X, "Local recurrence after radiofrequency ablation of hepatocellular carcinoma : treatment choice and outcome" 19 : 1466-1475, 2015
516 Seong J, "Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization" 47 : 1331-1335, 2000
517 Park W, "Local radiotherapy for patients with unresectable hepatocellular carcinoma" 61 : 1143-1150, 2005
518 Grant RC, "Living vs. deceased donor liver transplantation for hepatocellular carcinoma : a systematic review and meta-analysis" 27 : 140-147, 2013
519 Azoulay D, "Living or brain-dead donor liver transplantation for hepatocellular carcinoma : a multicenter, western, intent-to-treat cohort study" 266 : 1035-1044, 2017
520 Liang W, "Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma : a metaanalysis" 18 : 1226-1236, 2012
521 Kim JM, "Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection" 8 : 288-, 2020
522 Sugawara Y, "Living donor liver transplantation for hepatocellular carcinoma : Tokyo University series" 25 : 310-312, 2007
523 Kulik L, "Living donor liver transplantation for hepatocellular carcinoma" 127 (127): S277-S282, 2004
524 Sarasin FP, "Living donor liver transplantation for early hepatocellular carcinoma : a life-expectancy and costeffectiveness perspective" 33 : 1073-1079, 2001
525 Alim A, "Living donor liver transplantation : the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria" 28 : 10732748211011960-, 2021
526 한광협 ; 한대훈 ; 주동진 ; 김명수 ; 최기홍 ; 최진섭 ; 박영년 ; 성진실 ; 김순일, "Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy" 연세대학교의과대학 57 (57): 1276-1281, 2016
527 Vogl TJ, "Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads : results from the PRECISION V randomized trial" 197 : W562-W570, 2011
528 Kardashian A, "Liver transplantation outcomes in a U. S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria" 72 : 2014-2028, 2020
529 Mazzaferro V, "Liver transplantation in hepatocellular carcinoma after tumour downstaging(XXL) : a randomised, controlled, phase 2b/3 trial" 21 : 947-956, 2020
530 Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis" 334 : 693-699, 1996
531 Suh KS, "Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria" 25 : 329-333, 2007
532 Ravaioli M, "Liver transplantation for hepatocellular carcinoma : results of down-staging in patients initially outside the Milan selection criteria" 8 : 2547-2557, 2008
533 Yao FY, "Liver transplantation for hepatocellular carcinoma : expansion of the tumor size limits does not adversely impact survival" 33 : 1394-1403, 2001
534 Yao FY, "Liver transplantation for hepatocellular carcinoma : analysis of survival according to the intention-to-treat principle and dropout from the waiting list" 8 : 873-883, 2002
535 Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria" 143 : 986-994.e3, 2012
536 Chapman WC, "Liver transplantation for advanced hepatocellular carcinoma after downstaging without upfront stage restrictions" 224 : 610-621, 2017
537 Chong CC, "Liver stiffness measurement predicts high-grade post-hepatectomy liver failure : a prospective cohort study" 32 : 506-514, 2017
538 Rajakannu M, "Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma" 162 : 766-774, 2017
539 Wong JS, "Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes" 257 : 922-928, 2013
540 Fukami Y, "Liver resection for multiple hepatocellular carcinomas : a Japanese nationwide survey" 272 : 145-154, 2020
541 Lang H, "Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis" 92 : 198-202, 2005
542 Kokudo T, "Liver resection for hepatocellular carcinoma associated with hepatic vein invasion : a Japanese nationwide survey" 66 : 510-517, 2017
543 McDuffSGR, "Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis" 8 : 414-421, 2018
544 Belghiti J, "Liver hanging maneuver : a safe approach to right hepatectomy without liver mobilization" 193 : 109-111, 2001
545 Sangro B, "Liver disease induced by radioembolization of liver tumors : description and possible risk factors" 112 : 1538-1546, 2008
546 Reig M, "Liver cancer emergence associated with antiviral treatment : an immune surveillance failure?" 37 : 109-118, 2017
547 Monier A, "Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma : comparison between drug-eluting beads and lipiodol emulsion" 27 : 1431-1439, 2017
548 Gassmann D, "Liver allograft failure after nivolumab treatment-a case report with systematic literature research" 4 : e376-, 2018
549 Brown RS Jr, "Live donors in liver transplantation" 134 : 1802-1813, 2008
550 Simon TG, "Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis : results from a nationwide Swedish population" 171 : 318-327, 2019
551 Lencioni R, "Lipiodol transarterial chemoembolization for hepatocellular carcinoma : a systematic review of efficacy and safety data" 64 : 106-116, 2016
552 Cainap C, "Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma : results of a randomized phase III trial" 33 : 172-179, 2015
553 Hwang S, "Lessons learned from 1, 000 living donor liver transplantations in a single center : how to make living donations safe" 12 : 920-927, 2006
554 He MK, "Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma" 13 : 17588359211002720-, 2021
555 Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial" 391 : 1163-1173, 2018
556 Sho T, "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria" 50 : 966-977, 2020
557 Fu Z, "Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma(uHCC) : a retrospective controlled study" 15 : 663-675, 2021
558 Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)" 2022
559 Kabir T, "Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis : meta-analysis" 109 : 21-29, 2021
560 Han HS, "Laparoscopic versus open liver resection for hepatocellular carcinoma : case-matched study with propensity score matching" 63 : 643-650, 2015
561 Lee DH, "Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma : comparison of treatment outcomes" 10 : 25-37, 2021
562 Troisi RI, "Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis : multicentre propensity score-matched study" 108 : 196-204, 2021
563 Tamori A, "Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma" 26 : 77-80, 2003
564 Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease" 351 : 1521-1531, 2004
565 ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23CUPILT cohorts), "Lack of evidence of an effect of directacting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts" 65 : 734-740, 2016
566 Porrett PM, "Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era" 12 : 665-673, 2006
567 Cerny M, "LI-RADS version 2018 ancillary features at MRI" 38 : 1973-2001, 2018
568 Lee M, "Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas : six-month outcome analysis" 28 : 502-512, 2017
569 Korean Organ Donation Agency, "Korea Network for Organ Sharing (KONOS) Registry. 2017"
570 Korean Organ Donation Agency, "Korea Network for Organ Sharing (KONOS) Registry 2020"
571 KONOS, "KONOS annual report" KONOS 2019
572 The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B" 대한간학회 28 (28): 276-331, 2022
573 The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications" 대한간학회 24 (24): 169-229, 2018
574 Huang J, "Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?" 200 : 122-130, 2016
575 Cucchetti A, "Is portal hypertension a contraindication to hepatic resection?" 250 : 922-928, 2009
576 Famularo S, "Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection" 25 : 94-103, 2021
577 Delgado Martínez C, "Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations" 21 : 100225-, 2021
578 Gilbert ES, "Invited commentary : studies of workers exposed to low doses of radiation" 153 : 319-322, 2001
579 Lv J, "Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation" 46 : 2490-2497, 2021
580 Belghiti J, "Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis" 214 : 114-117, 1991
581 Poon RT, "Intrahepatic recurrence after curative resection of hepatocellular carcinoma : long-term results of treatment and prognostic factors" 229 : 216-222, 1999
582 Singal AG, "International liver cancer association(ILCA)white paper on biomarker development for hepatocellular carcinoma" 160 : 2572-2584, 2021
583 Llovet JM, "Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma : resection versus transplantation" 30 : 1434-1440, 1999
584 Bhangui P, "Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma : living versus deceased donor transplantation" 53 : 1570-1579, 2011
585 Yeung R, "Institutional analysis of stereotactic body radiotherapy(SBRT)for oligometastatic lymph node metastases" 12 : 105-, 2017
586 Hou JZ, "Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion" 84 : 362-368, 2012
587 Castro-Fernández M, "Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis" 29 : 11-14, 2006
588 Inoue M, "Influence of coffee drinking on subsequent risk of hepatocellular carcinoma : a prospective study in Japan" 97 : 293-300, 2005
589 Reynolds AR, "Infiltrative hepatocellular carcinoma : what radiologists need to know" 35 : 371-386, 2015
590 Feng M, "Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage : a phase 2 clinical trial" 4 : 40-47, 2018
591 Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population" 66 : 1454-1463, 2017
592 Sangiovanni A, "Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance" 126 : 1005-1014, 2004
593 Calvaruso V, "Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with directacting antiviral agents" 155 : 411-421.e4, 2018
594 Huang JF, "Incidence and clinical outcome of icteric type hepatocellular carcinoma" 17 : 190-195, 2002
595 Poon RT, "Improving survival results after resection of hepatocellular carcinoma : a prospective study of 377 patients over 10years" 234 : 63-70, 2001
596 Berry P, "Improving end of life care in liver disease" 76 : 1225-1226, 2022
597 Taketomi A, "Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation" 17 : 2283-2289, 2010
598 Kim TH, "Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma" 147 : 2693-2700, 2021
599 Andreou A, "Improved long-term survival after major resection for hepatocellular carcinoma : a multicenter analysis based on a new definition of major hepatectomy" 17 : 66-77, 2013
600 Chang TT, "Implementation of a multidisciplinary treatment team for hepatocellular cancer at a veterans affairs medical center improves survival" 10 : 405-411, 2008
601 Jackson R, "Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer : a metaanalysis of randomized phase III trials" 35 : 622-628, 2017
602 Lee HW, "Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B" 15 : 1083-1092, 2021
603 Nishio T, "Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection : a subgroup analysis of patients without chronic hepatitis viral infection" 163 : 264-269, 2018
604 Chan WH, "Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma" 113 : 789-795, 2016
605 Brenner DJ, "Impact of reduced patient life expectancy on potential cancer risks from radiologic imaging" 261 : 193-198, 2011
606 Decaens T, "Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma" 11 : 767-775, 2005
607 Agopian VG, "Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation : analysis of 3601 patients from the US multicenter HCC transplant consortium" 266 : 525-535, 2017
608 Lee JI, "Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus" 29 : 1019-1027, 2014
609 Kim WR, "Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B" 121 : 3631-3638, 2015
610 Incheon Kang ; 이재근 ; Sung Hoon Choi ; 김현정 ; 한대훈 ; 최기홍 ; 김명수 ; 최진섭 ; 김순일 ; 주동진, "Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma" 대한간학회 27 (27): 589-602, 2021
611 Sahakyan Y, "Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C : systematic review and meta-analysis" 28 : 739-754, 2021
612 Taketomi A, "Impact of des-gammacarboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation" 87 : 531-537, 2009
613 Ricke J, "Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma" 71 : 1164-1174, 2019
614 Ohki T, "Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib : a multicenter retrospective study" 7 : 141-149, 2020
615 Pinter M, "Immunotherapy for advanced hepatocellular carcinoma : a focus on special subgroups" 70 : 204-214, 2021
616 Hodi FS, "Immune-modified response evaluation criteria in solid tumors(imRECIST) : refining guidelines to assess the clinical benefit of cancer immunotherapy" 36 : 850-858, 2018
617 Chou R, "Imaging techniques for the diagnosis of hepatocellular carcinoma : a systematic review and meta-analysis" 162 : 697-711, 2015
618 Tanabe M, "Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging" 281 : 129-139, 2016
619 Roberts LR, "Imaging for the diagnosis of hepatocellular carcinoma : a systematic review and metaanalysis" 67 : 401-421, 2018
620 Jang KM, "Imaging features of subcentimeter hypointense nodules on gadoxetic acidenhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease" 56 : 526-535, 2015
621 Lee JM, "Imaging diagnosis and staging of hepatocellular carcinoma" 17 (17): S34-S43, 2011
622 Park S, "Image quality in liver CT : low-dose deep learning vs standard-dose model-based iterative reconstructions" 32 : 2865-2874, 2022
623 Riley TR 3rd, "Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C : a case series" 93 : 1563-1565, 1998
624 The 2007 recommendations of the International Commission on Radiological Protection, "ICRP publication 103" 37 : 1-332, 2007
625 Lou J, "Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus : a multi-center analysis" 19 : 668-, 2019
626 Parzen JS, "Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors : multi-institutional prospective results from the Proton Collaborative Group" 15 : 255-, 2020
627 Schwartz M, "How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?" 43 : 584-589, 2005
628 Guglielmi A, "How much remnant is enough in liver resection?" 29 : 6-17, 2012
629 Fan ST, "Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis" 130 : 198-203, 1995
630 김혜령 ; Mi Jang ; 박영년, "Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors" 대한간암학회 20 (20): 17-24, 2020
631 Kim YI, "Higher ratio of serum alphafetoprotein could predict outcomes in patients with hepatitis B virus-associated hepatocellular carcinoma and normal alanine aminotransferase" 11 : e0157299-, 2016
632 Jung IH, "High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma" 8 : 15182-15192, 2017
633 Staufer K, "High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation" 25 : 1158-1164, 2012
634 Mofredj A, "Hepatotoxicity caused by therapeutic doses of paracetamol in alcoholics. Report of 2 cases of fatal hepatitis in cirrhosis" 150 : 507-511, 1999
635 Uchino K, "Hepatocellular carcinoma with extrahepatic metastasis : clinical features and prognostic factors" 117 : 4475-4483, 2011
636 Kim J, "Hepatocellular carcinoma with extrahepatic metastasis : are there still candidates for transarterial chemoembolization as an initial treatment" 14 : e0213547-, 2019
637 Wang JH, "Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis : a randomized study in community" 108 : 416-424, 2013
638 Zhao C, "Hepatocellular carcinoma screening and surveillance : practice guidelines and real-life practice" 50 : 120-133, 2016
639 Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression" 67 : 1204-1212, 2017
640 Golfieri R, "Hepatocellular carcinoma responding to superselective transarterial chemoembolization : an issue of nodule dimension?" 24 : 509-517, 2013
641 Dutta D, "Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery : interim results of a prospective study" 40 : 389-401, 2021
642 Tseng CH, "Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B : a systematic review and meta-analysis" 5 : 1039-1052, 2020
643 Lewis S, "Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis" 200 : W610-W616, 2013
644 Chung JW, "Hepatocellular carcinoma and portal vein invasion : results of treatment with transcatheter oily chemoembolization" 165 : 315-321, 1995
645 Lee YJ, "Hepatocellular carcinoma : diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis" 275 : 97-109, 2015
646 Christian-Miller N, "Hepatocellular cancer pain : impact and management challenges" 5 : 75-80, 2018
647 전영은 ; 이한아 ; Jun Sik Yoon ; 박준용 ; Bo Hyun Kim ; In Joon Lee ; Suk Kyun Hong ; Dong Hyeon Lee ; Hyun-Joo Kong ; Eunyang Kim ; Young-Joo Won ; Jeong Hoon Lee, "Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry" 대한간암학회 20 (20): 135-147, 2020
648 Vernuccio F, "Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediatehigh risk observations, but not time to progression" 128 : 109018-, 2020
649 Benson AB, "Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology" 19 : 541-565, 2021
650 Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virusrelated hepatocellular carcinoma" 69 : 813-819, 2007
651 Jun BG, "Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment : a multicenter study" 13 : e0201316-, 2018
652 Dan JQ, "Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma : a retrospective study" 39 : 865-872, 2013
653 Lim S, "Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib" 30 : 1024-1031, 2015
654 World Health Organization (WHO), "Hepatitis B vaccines:WHO position paper" WHO 2017
655 Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy" 15 : 1661-1666, 2004
656 Chung JW, "Hepatic tumors : predisposing factors for complications of transcatheter oily chemoembolization" 198 : 33-40, 1996
657 Song KD, "Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm" 11 : 227-237, 2019
658 Lu L, "Hepatic resection versus transarterial chemoembolization for intermediate-stage hepatocellular carcinoma : a cohort study" 11 : 618937-, 2021
659 Yue YY, "Hepatic resection is associated with improved long-term survival compared to radio-frequency ablation in patients with multifocal hepatocellular carcinoma" 10 : 110-, 2020
660 Mullen JT, "Hepatic insufficiency and mortality in 1, 059noncirrhotic patients undergoing major hepatectomy" 204 : 854-862, 2007
661 Li QJ, "Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma : a randomized phase III trial" 40 : 150-160, 2022
662 Hamada A, "Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma : prognostic factors" 15 : 835-841, 2004
663 Takaki H, "Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advancedstage(Barcelona Clinic Liver Cancer stage-B or stage-C)hepatocellular carcinoma : multicenter phase-II clinical study" 20 : 745-754, 2015
664 Ueshima K, "Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma" 78 (78): 148-153, 2010
665 Kosaka Y, "Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein" 10 : 151-160, 2021
666 Yamakado K, "Hepatic arterial embolization for unresectable hepatocellular carcinomas : do technical factors affect prognosis?" 30 : 560-566, 2012
667 Hamaoka M, "Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy : a retrospective cohort study" 44 : 223-228, 2017
668 National Research Council, "Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2" National Academy of Sciences 2006
669 Kwon CH, "HCC in living donor liver transplantation : can we expand the Milan criteria?" 25 : 313-319, 2007
670 Sheu JC, "Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications" 89 : 259-266, 1985
671 Schünemann HJ, "Grading quality of evidence and strength of recommendations for diagnostic tests and strategies" 336 : 1106-1110, 2008
672 Guyatt GH, "Going from evidence to recommendations" 336 : 1049-1051, 2008
673 Jongerius IM, "Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO): a surgeon- and patient-blinded randomized controlled trial" 23 : 1578-1585, 2021
674 GBD 2013 Mortality and Causes of Death Collaborators, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013" 385 : 117-171, 2015
675 Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE study" 35 : 2155-2166, 2015
676 Lozano R, "Global and regional mortality from 235causes of death for 20 age groups in 1990 and 2010 : a systematic analysis for the global burden of disease study 2010" 380 : 2095-2128, 2012
677 Nihon Kangan K, "General rules for the clinical and pathological study of primary liver cancer" Kanehara & Co. 2010
678 Patrikidou A, "Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of antiangiogenic therapies" 32 : 1028-1035, 2014
679 Mir O, "Gemcitabine and oxaliplatin as secondline treatment in patients with hepatocellular carcinoma pretreated with sorafenib" 29 : 2793-2799, 2012
680 Haimerl M, "Gd-EOB-DTPA-enhanced MRI for evaluation of liver function : comparison between signal-intensity-based indices and T1 relaxometry" 7 : 43347-, 2017
681 Kim SH, "Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma" 192 : 1675-1681, 2009
682 Guyatt GH, "GRADE : an emerging consensus on rating quality of evidence and strength of recommendations" 336 : 924-926, 2008
683 Lencioni R, "GIDEON(Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) : second interim analysis" 68 : 609-617, 2014
684 Calandri M, "Fusion imaging and virtual navigation to guide percutaneous thermal ablation of hepatocellular carcinoma : a review of the literature" 42 : 639-647, 2019
685 Hayashi H, "Functional assessment versus conventional volumetric assessment in the prediction of operative outcomes after major hepatectomy" 157 : 20-26, 2015
686 Dioguardi Burgio M, "Follow-up imaging after liver transplantation should take into consideration primary hepatocellular carcinoma characteristics" 99 : 1613-1618, 2015
687 Ahn SJ, "Focal eosinophilic infiltration of the liver : gadoxetic acidenhanced magnetic resonance imaging and diffusionweighted imaging" 35 : 81-85, 2011
688 Li C, "FibroScan predicts ascites after liver resection for hepatitis B virusrelated hepatocellular carcinoma : a prospective cohort study" 20 : 21-25, 2015
689 Haberer JP, "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis" 54 : 1267-1270, 1982
690 Kim HC, "Feasibility of boosted radioembolization for hepatocellular carcinoma larger than 5 cm" 30 : 1-8, 2019
691 Shirai S, "Feasibility and efficacy of single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma 8 cm or more with portal vein tumor thrombus in combination with transcatheter arterial chemoembolization" 76 : 1037-1044, 2010
692 Terashima T, "Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib" 44 : 1179-1185, 2014
693 배선현 ; 김미숙 ; 조철구 ; 김금배 ; 박수철 ; 이동한 ; 한철주 ; 김용한, "Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma" 대한의학회 28 (28): 213-219, 2013
694 Shirabe K, "Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy : univariate and multivariate analyses" 14 : 802-805, 1991
695 Kim JH, "Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: a retrospective cohort study" 95 : e4735-, 2016
696 Rim CH, "External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium : a meta-analysis and systemic review" 129 : 123-129, 2018
697 Todo S, "Extending indication : role of living donor liver transplantation for hepatocellular carcinoma" 13 (13): S48-S54, 2007
698 Kim SS, "Extended application of subtraction arterial phase imaging in LI-RADS version 2018 : a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI" 31 : 1620-1629, 2021
699 Invernizzi F, "Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation" 104 : 568-574, 2020
700 Ito T, "Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation" 13 : 1637-1644, 2007
701 Lee SG, "Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one largevolume center" 14 : 935-945, 2008
702 Yao FY, "Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation : an intention-to-treat analysis" 48 : 819-827, 2008
703 Heimbach JK, "Evolution of liver transplant selection criteria and U. S. allocation policy for patients with hepatocellular carcinoma" 40 : 358-364, 2020
704 Liu D, "Evidence-based surveillance imaging schedule after liver transplantation for hepatocellular carcinoma recurrence" 101 : 107-111, 2017
705 Kokudo N, "Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan : the J-HCC guidelines" 44 (44): 119-121, 2009
706 Forner A, "Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma : are response evaluation criteria in solid tumors reliable?" 115 : 616-623, 2009
707 박수진 ; 최상준 ; 조윤아 ; 신동현 ; 김종만 ; 박철근 ; 하상윤, "Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection" 대한암학회 52 (52): 1145-1152, 2020
708 Fukubayashi K, "Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma : a comparative study using the propensity score matching method" 4 : 1214-1223, 2015
709 Kim HD, "Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival" 148 : 1371-1382, 2015
710 Ippolito D, "Estimating liver function in a large cirrhotic cohort : signal intensity of gadoliniumethoxybenzyl-diethylenetriamine penta-acetic acidenhanced MRI" 51 : 1438-1445, 2019
711 Yopp AC, "Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome" 21 : 1287-1295, 2014
712 Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : a meta-analysis of observational studies" 158 : 329-337, 2013
713 Lee JE, "Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma" 20 : 235-241, 2014
714 Sung Won Lee ; Jonggi Choi ; 김승업 ; Young-Suk Lim, "Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma" 대한간학회 27 (27): 402-412, 2021
715 Choi HeeKyoung ; Seo Gi Hyeon, "Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea" 대한의학회 36 (36): 1-10, 2021
716 Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis" 58 : 1537-1547, 2013
717 Zhou C, "Emergency transarterial embolization followed by staged hepatectomy versus emergency hepatectomy for ruptured hepatocellular carcinoma : a single-center, propensity score matched analysis" 38 : 1090-1098, 2020
718 Grudzen CR, "Emergency department-initiated palliative care in advanced cancer : a randomized clinical trial" 2 : 591-598, 2016
719 Wong RJ, "Elevated alpha-fetoprotein : differential diagnosis-hepatocellular carcinoma and other disorders" 19 : 309-323, 2015
720 Chuma M, "Efficacy of therapy for advanced hepatocellular carcinoma : intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation" 26 : 1123-1132, 2011
721 Brunner TB, "Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization(HERACLES : HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)" 11 : 653141-, 2021
722 Ogasawara S, "Efficacy of sorafenib in intermediatestage hepatocellular carcinoma patients refractory to transarterial chemoembolization" 87 : 330-341, 2014
723 Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5cm)hepatocellular carcinomas" 53 : 1580-1589, 2011
724 Li X, "Efficacy of prophylactic entecavir for hepatitis B virusrelated hepatocellular carcinoma receiving transcatheter arterial chemoembolization" 16 : 8665-8670, 2015
725 Vietti Violi N, "Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease : a randomised controlled phase 2 trial" 3 : 317-325, 2018
726 Kim K, "Efficacy of local therapy for oligometastatic hepatocellular carcinoma : a propensity score matched analysis" 8 : 35-44, 2021
727 d’Izarny-Gargas T, "Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer : a systematic review" 20 : 2457-2465, 2020
728 Yoon SM, "Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : a randomized clinical trial" 4 : 661-669, 2018
729 Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine" 384 : 403-416, 2021
730 Wong YJ, "Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients : a systematic review and meta-analysis" 55 : 615-623, 2021
731 Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : subanalyses of a phase III trial" 57 : 821-829, 2012
732 Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial" 10 : 25-34, 2009
733 Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH) : an openlabel randomised controlled phase 3 trial" 18 : 1624-1636, 2017
734 Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib : the CheckMate 040randomized clinical trial" 6 : e204564-, 2020
735 Kim BK, "Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma : a prospective phase 2 trial" 107 : 106-115, 2020
736 Goh MJ, "Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea" 10 : 52-62, 2021
737 Lee SG, "Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients : 24-month results from the pooled analysis of 2 randomized controlled trials" 105 : 1564-1575, 2021
738 Xin Wang ; Yanan Hu ; Mudan Ren ; Xinlan Lu ; Guifang Lu ; Shuixiang He, "Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis" 대한영상의학회 17 (17): 93-102, 2016
739 Alsina A, "Effects of subsequent systemic anticancer medication following first-line lenvatinib : a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma" 9 : 93-104, 2020
740 Luo W, "Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas : a systematic review and meta-analysis" 15 : 126-, 2017
741 Lao XM, "Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma" 33 : 595-604, 2013
742 Liu S, "Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy" 10 : 582504-, 2020
743 Calleja JL, "Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1infection : results from a spanish real-world cohort" 66 : 1138-1148, 2017
744 Xi M, "Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis" 8 : e63864-, 2013
745 Arizumi T, "Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization(TACE)refractory and intermediate-stage hepatocellular carcinoma" 4 : 253-262, 2015
746 Cheol-Hyung Lee ; Yun Bin Lee ; Minseok Albert Kim ; Heejoon Jang ; Hyunwoo Oh ; Sun Woong Kim ; Eun Ju Cho ; Kyung-Hun Lee ; Jeong-Hoon Lee ; Su Jong Yu ; Jung-Hwan Yoon ; Tae-You Kim ; Yoon Jun Kim, "Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment" 대한간학회 26 (26): 328-339, 2020
747 Brooks JT, "Effectiveness of mask wearing to control community spread of SARS-CoV-2" 325 : 998-999, 2021
748 Lee IJ, "Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients" 11 : 1758835919866072-, 2019
749 Lee SU, "Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis" 190 : 806-814, 2014
750 Rim CH, "Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement : a multicenter trial in Korea(KROG 17-10)" 96 : 759-766, 2020
751 Lee YS, "Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma : a multicenter, randomised, double-blind controlled study" 140 : 19-27, 2020
752 Ibrahim NM, "Effect of transcranial direct current stimulation of the motor cortex on visceral pain in patients with hepatocellular carcinoma" 19 : 550-560, 2018
753 Lee HW, "Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B" 28 : 1570-1578, 2021
754 Chu SS, "Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib : a nationwide cancer-registry-based study" 11 : 1614-, 2021
755 Lv N, "Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma : a prospective randomized trial" 26 : 3492-3499, 2016
756 Sohn W, "Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma" 7 : 47794-47807, 2016
757 Ackerman Z, "Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis : results of a double-blind placebo-controlled parallel group study" 97 : 2033-2039, 2002
758 Lee S, "Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation" 273 : 564-571, 2021
759 Zhu AX, "Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib : the EVOLVE-1 randomized clinical trial" 312 : 57-67, 2014
760 Yin J, "Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma : a two-stage longitudinal clinical study" 31 : 3647-3655, 2013
761 이광식 ; 장후선 ; 이선미 ; 박은철, "Economic Burden of Cancer in Korea during 2000-2010" 대한암학회 47 (47): 387-398, 2015
762 Lencioni R, "Early-stage hepatocellular carcinoma in patients with cirrhosis : long-term results of percutaneous image-guided radiofrequency ablation" 234 : 961-967, 2005
763 Huang G, "Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load" 20 : 1482-1490, 2013
764 Bakitas MA, "Early versus delayed initiation of concurrent palliative oncology care : patient outcomes in the ENABLE III randomized controlled trial" 33 : 1438-1445, 2015
765 Oh D, "Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization : a prospective evaluation of efficacy and toxicity" 33 : 370-375, 2010
766 Sho T, "Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting" 4 : 54-60, 2020
767 Sho T, "Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria" 51 : 979-989, 2021
768 Temel JS, "Early palliative care for patients with metastatic non-small-cell lung cancer" 363 : 733-742, 2010
769 Zimmermann C, "Early palliative care for patients with advanced cancer : a cluster-randomised controlled trial" 383 : 1721-1730, 2014
770 Conti F, "Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals" 65 : 727-733, 2016
771 Hayakawa Y, "Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice" 40 : 392-402, 2022
772 Yamanaka K, "Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma" 47 : 343-346, 2012
773 Portolani N, "Early and late recurrence after liver resection for hepatocellular carcinoma : prognostic and therapeutic implications" 243 : 229-235, 2006
774 European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma" 56 : 908-943, 2012
775 European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma" 69 : 182-236, 2018
776 European Association for the Study of the Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection" 57 : 167-185, 2012
777 Lin CY, "Dynamic-contrastenhanced magnetic resonance imaging of cirrhotic liver parenchyma : a comparison between gadolinium-diethylenetriamine pentaacetic acid and gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid" 78 : 666-672, 2015
778 Robert C, "Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma" 36 : 1668-1674, 2018
779 UFaDAF UDoHaHS, "Drugs: acetaminophen information"
780 Zanetto A, "Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals" 23 : 1103-1112, 2017
781 Chong JU, "Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus" 25 : 3308-3315, 2018
782 Mehta N, "Downstaging outcomes for hepatocellular carcinoma : results from the multicenter evaluation of reduction in tumor size before liver transplantation(MERITS-LT)consortium" 161 : 1502-1512, 2021
783 Yao FY, "Downstaging of hepatocellular cancer before liver transplant : long-term outcome compared to tumors within Milan criteria" 61 : 1968-1977, 2015
784 Parikh ND, "Downstaging hepatocellular carcinoma : a systematic review and pooled analysis" 21 : 1142-1152, 2015
785 Yoon JH, "Double lowdose dual-energy liver CT in patients at high-risk of HCC : a prospective, randomized, single-center study" 55 : 340-348, 2020
786 Kim TH, "Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy" 67 : 225-231, 2007
787 Lee JG, "Donor safety in living donor liver transplantation : the Korean organ transplantation registry study" 23 : 999-1006, 2017
788 Shin M, "Donor morbidity including biliary complications in livingdonor liver transplantation : single-center analysis of 827cases" 93 : 942-948, 2012
789 Ghobrial RM, "Donor morbidity after living donation for liver transplantation" 135 : 468-476, 2008
790 Qin S, "Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma : a randomized, openlabel, parallel-controlled phase II-III trial" 39 : 3002-3011, 2021
791 Dart RC, "Does therapeutic use of acetaminophen cause acute liver failure?" 27 : 1219-1230, 2007
792 Lazzara C, "Does the margin width influence recurrence rate in liver surgery for hepatocellular carcinoma smaller than 5 cm?" 21 : 523-529, 2017
793 Lin N, "Does the intermittent pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review" 15 : e0229870-, 2020
794 Basha MAA, "Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study" 28 : 2592-2603, 2018
795 Cho Y, "Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?" 9 : e105679-, 2014
796 Mendizabal M, "Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents" 18 : 2554-2563.e3, 2020
797 Jansen YJL, "Discontinuation of anti-PD-1antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma" 30 : 1154-1161, 2019
798 Cabibbo G, "Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients" 71 : 265-273, 2019
799 Poon RT, "Differentiating early and late recurrences after resection of HCC in cirrhotic patients : implications on surveillance, prevention, and treatment strategies" 16 : 792-794, 2009
800 성필수 ; 배시현 ; 장정원 ; 송도선 ; 김희언 ; 유선홍 ; 박정화 ; 권정현 ; 송명준 ; 유찬란 ; 최종영 ; 윤승규, "Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization" 대한간학회 17 (17): 299-306, 2011
801 Nakamura Y, "Diagnostic value of deep learning reconstruction for radiation dose reduction at abdominal ultra-high-resolution CT" 31 : 4700-4709, 2021
802 Lee JE, "Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan" 18 : 2979-2987, 2012
803 Hammerstingl R, "Diagnostic efficacy of gadoxetic acid(primovist)-enhanced MRI and spiral CT for a therapeutic strategy : comparison with intraoperative and histopathologic findings in focal liver lesions" 18 : 457-467, 2008
804 Choi SH, "Diagnostic criteria for hepatocellular carcinoma ≤3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging" 64 : 1099-1107, 2016
805 Tateishi R, "Diagnostic accuracy of tumor markers for hepatocellular carcinoma : a systematic review" 2 : 17-30, 2008
806 Joo I, "Diagnostic accuracy of liver imaging reporting and data system(LI-RADS)v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI" 44 : 1330-1338, 2016
807 이상민 ; 이정민 ; 안수좌 ; Hyo-Jin Kang ; 양현경 ; Jeong Hee Yoon, "Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018" 대한영상의학회 22 (22): 1066-1076, 2021
808 Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases" 68 : 723-750, 2018
809 Forner A, "Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis : prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma" 47 : 97-104, 2008
810 El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma" 126 : 460-468, 2004
811 Yang H, "Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma : a randomized, doubleblinded, placebo-controlled study" 28 : 1503-1511.e2, 2017
812 Brouwers MC, "Development of the AGREE II, part 2 : assessment of validity of items and tools to support application" 182 : E472-E478, 2010
813 Brouwers MC, "Development of the AGREE II, part 1 : performance, usefulness and areas for improvement" 182 : 1045-1052, 2010
814 Cho HJ, "Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver" 112 : 460-470, 2017
815 Berardi G, "Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis" 72 : 75-84, 2020
816 Yau T, "Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma" 146 : 1691-1700, 2014
817 Singal AG, "Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial : where did surveillance fail?" 108 : 425-432, 2013
818 Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma" 100 : 698-711, 2008
819 Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma" 138 : 493-502, 2010
820 Blumenthal KG, "Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2" 384 : 1273-1277, 2021
821 Chang MH, "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees : a 20-year follow-up study" 101 : 1348-1155, 2009
822 Young S, "Current trends in the treatment of hepatocellular carcinoma with transarterial embolization : a cross-sectional survey of techniques" 29 : 3287-3295, 2019
823 Durand-Labrunie J, "Curative irradiation treatment of hepatocellular carcinoma : a multicenter phase 2 trial" 107 : 116-125, 2020
824 Parikh ND, "Costeffectiveness of hepatocellular carcinoma surveillance : an assessment of benefits and harms" 115 : 1642-1649, 2020
825 Cho JY, "Costeffectiveness of adjuvant immunotherapy with cytokineinduced killer cell for hepatocellular carcinoma based on a randomized controlled trial and real-world data" 11 : 728740-, 2021
826 Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class a cirrhosis" 101 : 422-434, 1996
827 Tanaka H, "Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography" 42 : 376-384, 2012
828 Andersson KL, "Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis" 6 : 1418-1424, 2008
829 Llovet JM, "Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation" 50 : 123-128, 2002
830 Kubota K, "Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma" 3 : 990-994, 2012
831 Huda W, "Converting dose-length product to effective dose at CT" 248 : 995-1003, 2008
832 Sacco R, "Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma" 22 : 1545-1552, 2011
833 Zhong J, "Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma : a systematic review" 2 : 1091-1096, 2014
834 Kang HJ, "Contrastenhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk" 297 : 108-116, 2020
835 Terzi E, "Contrast ultrasound LI-RADS LR-5identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules" 68 : 485-492, 2018
836 Das A, "Contemporary systematic review of healthrelated quality of life outcomes in locoregional therapies for hepatocellular carcinoma" 30 : 1924-1933, 2019
837 Zeng ZC, "Consideration of role of radiotherapy for lymph node metastases in patients with HCC : retrospective analysis for prognostic factors from 125 patients" 63 : 1067-1076, 2005
838 Park JW, "Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma(EPOIHCC)" 33 : 327-337, 2013
839 Wang X, "Consensus guidelines for the use of fluorescence imaging in hepatobiliary surgery" 274 : 97-106, 2021
840 Park HC, "Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert meeting(APPLE 2014) : current practice and future clinical trials" 5 : 162-174, 2016
841 Wattanasatesiri T, "Cone-beam CT-guided chemoembolization in patients with complete response after previous chemoembolization but subsequent elevated α-fetoprotein without overt hepatocellular carcinoma" 30 : 1273-1280, 2019
842 Kang YK, "Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation" 29 : 6009-6017, 2019
843 Shim JH, "Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection" 17 : 869-877, 2010
844 Eguchi S, "Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey" 143 : 469-475, 2008
845 Lee SW, "Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea : a large-scale, propensity score analysis" 69 : 1301-1308, 2020
846 Govalan R, "Comparison of surgical resection and systemic treatment for hepatocellular carcinoma with vascular invasion : national cancer database analysis" 10 : 407-418, 2021
847 Wang Q, "Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria : a metaanalysis" 91 : E432-E438, 2021
848 Wei CY, "Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma" 8 : 238-, 2020
849 Ko SE, "Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma" 37 : 1354-1361, 2020
850 Kodama K, "Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis" 94 : 215-222, 2018
851 Joo Hyun Oh ; Dong Hyun Sinn ; Gyu-Seong Choi ; Jong Man Kim ; Jae-Won Joh ; Tae Wook Kang ; Dongho Hyun ; Wonseok Kang ; Geum-Youn Gwak ; Yong-Han Paik ; Joon Hyeok Lee ; Kwang Cheol Koh ; Seung Woon Paik ; Moon Seok Choi, "Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria" 대한외과학회 99 (99): 238-246, 2020
852 Kim KH, "Comparison of open and laparoscopic live donor left lateral sectionectomy" 98 : 1302-1308, 2011
853 Tan W, "Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma : a systematic review and metaanalysis" 36 : 264-272, 2019
854 Miyayama S, "Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≤6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography" 37 : 388-395, 2014
855 Zhao Q, "Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis : a meta-analysis" 13 : 21-31, 2016
856 Kawaoka T, "Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma" 16 : 505-512, 2015
857 Kim GA, "Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis : a propensity score analysis" 26 : 320-329.e6, 2015
858 Kaibori M, "Comparison of anatomic and nonanatomic hepatic resection for hepatocellular carcinoma" 24 : 616-626, 2017
859 이선영 ; Seung-seob Kim ; Dong ryul Chang ; Hyerim Kim ; Myeong-Jin Kim, "Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging" 대한간학회 26 (26): 340-351, 2020
860 Sposito C, "Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation : a case-control study" 59 : 59-66, 2013
861 Dave S, "Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B : a systematic review and meta-analysis" 73 : 68-78, 2021
862 Lewis S, "Comparative assessment of standard and immune response criteria for evaluation of response to PD-1monotherapy in unresectable HCC" 47 : 969-980, 2022
863 Lee J, "Comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma : a multi-center, propensity score study" 10 : 4045-, 2021
864 Hanna RF, "Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma" 41 : 71-90, 2016
865 Kornberg A, "Combining 18F-FDG positron emission tomography with up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma" 7 : 14176-, 2017
866 Zaitoun MMA, "Combined therapy with conventional trans-arterial chemoembolization(cTACE)and microwave ablation(MWA)for hepatocellular carcinoma >3-<5 cm" 38 : 248-256, 2021
867 Zhou C, "Combined hepatocellular carcinoma-cholangiocarcinoma : MRI features correlated with tumor biomarkers and prognosis" 32 : 78-88, 2022
868 Park MS, "Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis" 71 : 165-173, 2013
869 Lin J, "Combination treatment including targeted therapy for advanced hepatocellular carcinoma" 7 : 71036-71051, 2016
870 Liu L, "Combination therapy of sorafenib and TACE for unresectable HCC : a systematic review and meta-analysis" 9 : e91124-, 2014
871 Koo JE, "Combination of transarterial chemoembolization and threedimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus" 78 : 180-187, 2010
872 Bravi F, "Coffee reduces risk for hepatocellular carcinoma : an updated meta-analysis" 11 : 1413-1421.e1, 2013
873 Gelatti U, "Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology : a case-control study" 42 : 528-534, 2005
874 Rhee H, "Clinico-radio-pathological and molecular features of hepatocellular carcinomas with keratin 19 expression" 9 : 663-681, 2020
875 Kim HY, "Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma : past, present, and future" 3 : 9-17, 2014
876 Meier V, "Clinical staging of hepatocellular carcinoma" 27 : 131-141, 2009
877 Yu JI, "Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma" 8 : 6986-6994, 2019
878 Shimose S, "Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study" 12 : 1867-, 2020
879 Komatsu S, "Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma" 117 : 4890-4904, 2011
880 Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : the Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update" 49 : 1109-1113, 2019
881 Yoo C, "Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : a multinational multicenter retrospective study" 10 : 107-114, 2021
882 Chang JI, "Clinical outcomes of hepatitis B virus-related hepatocellular carcinoma patients with undetectable serum HBV DNA levels" 67 : 4565-4573, 2022
883 Kwak HW, "Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area" 29 : 820-829, 2014
884 Carrat F, "Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment : a prospective cohort study" 393 : 1453-1464, 2019
885 Yoo DJ, "Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma : does transarterial chemoembolization improve survival in these patients?" 26 : 145-154, 2011
886 Choi HJ, "Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation" 19 : 4737-4744, 2013
887 Bruix J, "Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver" 35 : 421-430, 2001
888 Tanaka K, "Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection" 32 : 1738-1747, 2008
889 He J, "Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy" 115 : 2710-2720, 2009
890 Chan DL, "Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma-a systematic review" 22 : e23-e30, 2013
891 Cho YY, "Clinical characteristics of long-term survivors after sorafenib treatment for unresectable hepatocellular carcinoma : a Korean national multicenter retrospective cohort study" 8 : 613-623, 2021
892 차혜정 ; 박희철 ; 유정일 ; 김태현 ; 남택근 ; 윤상민 ; 윤원섭 ; 김준원 ; 김미숙 ; 장홍석 ; 최영민 ; 김진희 ; 계철승 ; 정인경 ; 성진실, "Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)" 대한암학회 49 (49): 61-69, 2017
893 Yang H, "Chronic liver disease independently associated with COVID-19 severity : evidence based on adjusted effect estimates" 15 : 217-222, 2021
894 Zhou B, "Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation" 21 : 333-338, 2010
895 Malagari K, "Chemoembolization with doxorubicineluting beads for unresectable hepatocellular carcinoma : five-year survival analysis" 35 : 1119-1128, 2012
896 Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics" 46 : 474-481, 2007
897 Kudo M, "CheckMate 040 cohort 5 : a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis" 75 : 600-609, 2021
898 Bolondi L, "Characterization of small nodules in cirrhosis by assessment of vascularity : the problem of hypovascular hepatocellular carcinoma" 42 : 27-34, 2005
899 Jung SM, "Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma" 23 : 304-311, 2019
900 Chan AC, "Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening" 247 : 666-673, 2008
901 Tripodi A, "Changing concepts of cirrhotic coagulopathy" 112 : 274-281, 2017
902 Lao XM, "Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma" 41 : 553-563, 2011
903 Hong SH, "Change in cancer pain management in Korea between 2001 and 2006 : results of two nationwide surveys" 41 : 93-103, 2011
904 World Health Organization (WHO), "Cancer pain relief: with a guide to opioid availability"
905 Ministry of Health & Welfare, "Cancer pain management guideline"
906 Takahashi H, "Can low-dose CT with iterative reconstruction reduce both the radiation dose and the amount of iodine contrast medium in a dynamic CT study of the liver?" 83 : 684-691, 2014
907 Qin S, "Camrelizumab in patients with previously treated advanced hepatocellular carcinoma : a multicentre, open-label, parallel-group, randomised, phase 2 trial" 21 : 571-580, 2020
908 Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma" 379 : 54-63, 2018
909 Wilson SR, "CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI" 43 : 127-142, 2018
910 Johnson PJ, "Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma : results from the randomized phase III BRISK-FL study" 31 : 3517-3524, 2013
911 Llovet JM, "Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed : results from the randomized phase III BRISK-PS study" 31 : 3509-3516, 2013
912 Kollmann D, "Bridging to liver transplantation in HCC patients" 402 : 863-871, 2017
913 Choi HJ, "Brain metastases from hepatocellular carcinoma : prognostic factors and outcome : brain metastasis from HCC" 91 : 307-313, 2009
914 Garin E, "Boosted selective internal radiation therapy with 90Y-loaded glass microspheres(B-SIRT)for hepatocellular carcinoma patients : a new personalized promising concept" 40 : 1057-1068, 2013
915 Schwarz L, "Bleeding recurrence and mortality following interventional management of spontaneous HCC rupture : results of a multicenter European study" 42 : 225-232, 2018
916 Sherman M, "Biopsy for liver cancer : how to balance research needs with evidence-based clinical practice" 61 : 433-436, 2015
917 Choi SI, "Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea : changes in 16-years cohorts" 17 : e0265668-, 2022
918 Wells ML, "Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma" 42 : 2623-2631, 2017
919 Sapisochin G, "Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series" 22 : 2286-2294, 2015
920 Terashima T, "Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma" 6 : 236-249, 2017
921 Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : the 2022update" 76 : 681-693, 2022
922 Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis" 64 : 7099-7109, 2004
923 Bril F, "Autoimmune hepatitis developing after coronavirus disease 2019(COVID-19)vaccine : causality or casualty?" 75 : 222-224, 2021
924 Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma" 382 : 1894-1905, 2020
925 Serper M, "Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality" 152 : 1954-1964, 2017
926 Jang JW, "Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy" 71 : 546-555, 2020
927 Lee YB, "Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B" 73 : 2266-2277, 2021
928 Setiawan VW, "Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort" 148 : 118-125, 2015
929 Simon TG, "Association of aspirin with hepatocellular carcinoma and liver-related mortality" 382 : 1018-1028, 2020
930 Wang S, "Association of aspirin therapy with risk of hepatocellular carcinoma : a systematic review and doseresponse analysis of cohort studies with 2. 5 million participants" 151 : 104585-, 2020
931 Simon TG, "Association between aspirin use and risk of hepatocellular carcinoma" 4 : 1683-1690, 2018
932 Li X, "Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies" 7 : 569759-, 2021
933 Jang H, "Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis" 76 : 492-501, 2022
934 Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update" 10 : 1-98, 2016
935 Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update" 11 : 317-370, 2017
936 Kim DH, "Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma" 71 : 534-542, 2019
937 Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial" 359 : 1734-1739, 2002
938 Lyu N, "Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma : a biomolecular exploratory, randomized, phase III trial(FOHAIC-1)" 40 : 468-480, 2022
939 Qin S, "Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma(AHELP) : a multicentre, doubleblind, randomised, placebo-controlled, phase 3 trial" 6 : 559-568, 2021
940 Huang G, "Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma : a randomized controlled trial" 261 : 56-66, 2015
941 Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : a systematic review and metaanalysis" 63 : 284-306, 2016
942 Huang L, "Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy : a randomized controlled trial" 20 : 336-342, 2013
943 Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment" 66 : 1556-1569, 2017
944 Lee HL, "Anticancer effect of statins in patients undergoing liver transplantation for hepatocellular carcinoma" 28 : 397-406, 2022
945 Tang JX, "Anterior vs conventional approach right hepatic resection for large hepatocellular carcinoma : a systematic review and metaanalysis" 23 : 7917-7929, 2017
946 Korean Central Cancer Registry, "Annual report of Korean central cancer registry (2019)" Korea Central Cancer Registry 2019
947 Korean Central Cancer Registry, "Annual report of Korean central cancer registry (2015)" Korea Central Cancer Registry 2015
948 Zhao H, "Anatomical versus non-anatomical resection for solitary hepatocellular carcinoma without macroscopic vascular invasion : a propensity score matching analysis" 32 : 870-878, 2017
949 Cucchetti A, "Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma" 155 : 512-521, 2014
950 Moris D, "Anatomic versus nonanatomic resection for hepatocellular carcinoma : a systematic review and meta-analysis" 44 : 927-938, 2018
951 Sun Z, "Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion : a systematic review and metaanalysis" 44 : 1143-1150, 2021
952 Kudo A, "Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion" 207 : 863-869, 2014
953 Wakai T, "Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma" 14 : 1356-1365, 2007
954 Oshiro Y, "Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma" 123 : 240-245, 2017
955 Shimada K, "Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma" 14 : 2337-2347, 2007
956 Ando Y, "Analysis of post-progression survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib" 98 : 787-797, 2020
957 Pelletier SJ, "An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data" 15 : 859-868, 2009
958 Burak KW, "An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma(HCC) : the Alberta HCC algorithm" 24 : 643-650, 2010
959 Mehta N, "Alphafetoprotein decrease from > 1, 000 to < 500 ng/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes" 69 : 1193-1205, 2019
960 Aghoram R, "Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B" 2012 : CD002799-, 2012
961 Marrero JA, "Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma" 42 : 218-224, 2005
962 Iakova P, "Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest" 113 : 495-506, 2003
963 Poon RT, "Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy" 195 : 311-318, 2002
964 Kang TW, "Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation : risk factors and clinical significance" 276 : 274-285, 2015
965 de Baère T, "Adverse events during radiofrequency treatment of 582 hepatic tumors" 181 : 695-700, 2003
966 Takayama T, "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma : a randomised trial" 356 : 802-807, 2000
967 Liao M, "Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma : a meta-analysis" 52 : 624-634, 2017
968 Zhu XD, "Adjuvant therapies after curative treatments for hepatocellular carcinoma : current status and prospects" 7 : 359-369, 2020
969 Jacob R, "Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with nonresectable hepatocellular carcinoma tumours of ≥ 3 cm" 17 : 140-149, 2015
970 Bruix J, "Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM) : a phase 3, randomised, double-blind, placebo-controlled trial" 16 : 1344-1354, 2015
971 Hong Y, "Adjuvant intrahepatic injection iodine-131-lipiodol improves prognosis of patients with hepatocellular carcinoma after resection : a meta-analysis" 77 (77): 1227-1232, 2015
972 Wang H, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis" 48 : 1275-1282, 2016
973 Lee JH, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma" 148 : 1383-1391, 2015
974 Yoon JS, "Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma : a propensity score-matched analysis of real-world data" 19 : 523-, 2019
975 John BV, "Addition of [18F]fluorodeoxyglucose positron emission tomography with computed tomography to cross-sectional imaging improves staging and alters management in hepatocellular carcinoma" 26 : 774-784, 2020
976 Larson AM, "Acetaminophen-induced acute liver failure : results of a United States multicenter, prospective study" 42 : 1364-1372, 2005
977 Colli A, "Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma : a systematic review" 101 : 513-523, 2006
978 van der Pol CB, "Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review" 156 : 976-986, 2019
979 Gupta P, "Abbreviated MRI for hepatocellular carcinoma screening : a systematic review and meta-analysis" 75 : 108-119, 2021
980 Chan A, "ALPPS versus portal vein embolization for hepatitisrelated hepatocellular carcinoma : a changing paradigm in modulation of future liver remnant before major hepatectomy" 273 : 957-965, 2021
981 Loomba R, "AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : expert review" 158 : 1822-1830, 2020
982 Yamamoto K, "AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC" 45 : 1272-1282, 2010
983 Pandanaboyana S, "A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection" 157 : 690-698, 2015
984 Roayaie S, "A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma" 137 : 850-855, 2009
985 Singal AG, "A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus" 8 : 280-288.e1, 2010
986 Torzilli G, "A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers : is it adherent to the EASL/AASLD recommendations? : An observational study of the HCC east-west study group" 257 : 929-937, 2013
987 Shi Y, "A recent advance in image-guided locoregional therapy for hepatocellular carcinoma" 3 : 90-102, 2016
988 Hui D, "A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma" 41 : 36-41, 2009
989 Heard K, "A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol(acetaminophen)administration in subjects who consume moderate amounts of alcohol" 26 : 283-290, 2007
990 Huang J, "A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria" 252 : 903-912, 2010
991 Ogasawara S, "A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization" 67 : 575-585, 2018
992 Yu X, "A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma" 34 : 194-203, 2014
993 Xu L, "A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma" 5 : e1083671-, 2016
994 Shiina S, "A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma" 129 : 122-130, 2005
995 Feng K, "A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma" 57 : 794-802, 2012
996 Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization" 43 : 233-240, 2006
997 Woo HY, "A randomized comparative study of high-dose and lowdose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma" 65 : 373-382, 2010
998 Yao FY, "A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation" 11 : 1505-1514, 2005
999 Fukumitsu N, "A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma" 74 : 831-836, 2009
1000 Chen MS, "A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma" 243 : 321-328, 2006
1001 Hae Won Lee ; Jeong Min Lee ; Jung-Hwan Yoon ; Yoon Jun Kim4 ; Joong-Won Park ; Sang-Jae Park ; Seong Hoon Kim ; Nam-Joon Yi ; Kyung-Suk Suh, "A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma" 대한외과학회 94 (94): 74-82, 2018
1002 Choi C, "A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma" 90 : 1051-1060, 2014
1003 Park JW, "A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma" 49 : 1912-1921, 2008
1004 Hsiao CY, "A prospective assessment of the diagnostic value of contrast-enhanced ultrasound, dynamic computed tomography and magnetic resonance imaging for patients with small liver tumors" 8 : 1353-, 2019
1005 Cheng SH, "A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma" 14 : 1025-1033, 1999
1006 Schefter TE, "A phase I trial of stereotactic body radiation therapy(SBRT)for liver metastases" 62 : 1371-1378, 2005
1007 Iwata H, "A phase 2 study of image-guided proton therapy for operable or ablation-treatable primary hepatocellular carcinoma" 111 : 117-126, 2021
1008 Jang WI, "A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma : safety and efficacy" 126 : 363-372, 2020
1009 Hwang SH, "A new reporting system for diagnosis of hepatocellular carcinoma in chronic hepatitis B with clinical and gadoxetic acid-enhanced MRI features" 55 : 1877-1886, 2022
1010 Kim SU, "A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea" 71 : 456-464, 2019
1011 Suzuki E, "A multicenter phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class" 48 : 317-321, 2018
1012 Koneru B, "A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma" 241 : 622-628, 2005
1013 Kimura T, "A multi-institutional retrospective study of repeated stereotactic body radiation therapy for intrahepatic recurrent hepatocellular carcinoma" 108 : 1265-1275, 2020
1014 Huang J, "A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy" 139 : 1709-1719, 2013
1015 Tan DJH, "A meta-analysis on the rate of hepatocellular carcinoma recurrence after liver transplant and associations to etiology, alpha-fetoprotein, income and ethnicity" 10 : 238-, 2021
1016 Huang X, "A meta-analysis comparing the effect of anatomical resection vs. non-anatomical resection on the long-term outcomes for patients undergoing hepatic resection for hepatocellular carcinoma" 19 : 843-849, 2017
1017 Feng X, "A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence" 19 : 667-674, 2017
1018 Yang JD, "A comparative study of postoperative outcomes between minimally invasive living donor hepatectomy and open living donor hepatectomy : the Korean organ transplantation registry" 170 : 271-276, 2021
1019 Song DS, "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis" 50 : 445-454, 2015
1020 Lewandowski RJ, "A comparative analysis of transarterial downstaging for hepatocellular carcinoma : chemoembolization versus radioembolization" 9 : 1920-1928, 2009
1021 Santagostino E, "A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus" 102 : 78-82, 2003
1022 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma" 대한영상의학회 20 (20): 1042-1113, 2019
1023 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma" 거트앤리버 소화기연관학회협의회 13 (13): 227-299, 2019
1024 Korean Liver Cancer Study Group ; National Cancer Center, Korea, "2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma" 대한영상의학회 16 (16): 465-522, 2015
1025 한국 간 암 스터디그룹 ; 국립 암 센터, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma" 거트앤리버 소화기연관학회협의회 9 (9): 267-317, 2015
1026 Lim C, "18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: a prospective observational study" 21 : 739-747, 2019
1027 Lin CY, "18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma : a systematic review and meta-analysis" 81 : 2417-2422, 2012
1028 Sugiyama M, "18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma" 39 : 961-968, 2004

동일학술지(권/호) 다른 논문

Use of “Diagnostic Yield” in Imaging Research Reports: Results from Articles Published in Two General Radiology Journals
- 대한영상의학회
- Park Ho Young
- 2022
- KCI등재,SCIE,SCOPUS
Randomized Clinical Trials of Artificial Intelligence in Medicine: Why, When, and How?
- 대한영상의학회
- Park Seong Ho
- 2022
- KCI등재,SCIE,SCOPUS
Prediction of Decompensation and Death in Advanced Chronic Liver Disease Using Deep Learning Analysis of Gadoxetic Acid-Enhanced MRI
- 대한영상의학회
- Heo Subin
- 2022
- KCI등재,SCIE,SCOPUS
Use of Artificial Intelligence for Reducing Unnecessary Recalls at Screening Mammography: A Simulation Study
- 대한영상의학회
- Kim Yeon Soo
- 2022
- KCI등재,SCIE,SCOPUS

분석정보

활용도 분석

논문 주제 분석

연구자 주제 분석

View

상세정보조회

usage

원문다운로드

대출신청

복사신청

EDDS신청

동일 주제 내 활용도 TOP

연도별 연구동향

연도별 활용동향

연관논문

연구자 네트워크 맵

공동연구자 (0)
유사연구자 (0) 활용도상위20명

연관 공개강의

인용하기

내책장담기

닫기

표가 있는 항목은 반드시 기재해 주셔야 합니다.

동일자료를 같은 책장에 담을 경우 담은 시점만 최신으로 수정됩니다.

책장선택
새 책장 만들어 자료 담기
선택한 자료

취소 내책장에 담기

새책장 만들기

닫기

표가 있는 항목은 반드시 기재해 주셔야 합니다.

새책장 명
새책장 설명

책장설명은 [내 책장/책장목록]에서 수정할 수 있습니다.
새책장 카테고리
- 카테고리
  취소
- 카테고리
  취소
- 카테고리
  취소
책장카테고리 설정은 최소1개 ~ 최대3개까지 가능합니다.
Default 설정
설정
선택한 자료

취소 새 책장 만들어 자료 담기

관심분야 검색

닫기

트리 또는 검색을 통해 관심분야를 선택 하신 후 등록 버튼을 클릭 하십시오.

관심분야 검색 결과
대분류	중분류	관심분야명
검색결과가 없습니다.

선택된 분야 (선택분야는 최소 하나 이상 선택 하셔야 합니다.)

카테고리
취소
카테고리
취소
카테고리
취소

등록

소장기관 정보

닫기

담당자
부서명
연락처
홈페이지
전자메일
주소
상호대차
문헌복사

문헌복사 및 대출서비스 정책은 제공도서관 규정에 따라 상이할수 있음

권호소장정보

닫기

오류접수

닫기

오류접수

[ 논문 정보 ]

[ 신청자 정보 ]

아이디
전화번호
- - SMS알림요청동의
오류내용

※ 개인정보 노출 방지를 위해 민감한 개인정보 내용은 가급적 기재를 자제하여 주시기 바랍니다.
(상담을 위해 불가피하게 개인정보를 기재하셔야 한다면, 가능한 최소한의 개인정보를 기재하여 주시기 바랍니다.)
메일주소
작성하신 내용을 완료하시려면 [보내기] 버튼을, 수정하시려면 [수정]버튼을 눌러주세요.

취소 오류접수 수정 보내기

오류 접수 확인

닫기

오류 접수 확인

고객님, 오류접수가 정상적으로 신청 되었습니다.

문의하신 내용은 3시간 이내에 메일로 답변을 드릴 수 있도록 하겠습니다.

다만, 고객센터 운영시간(평일 09:00 ~ 18:00) 이외에는

처리가 다소 지연될 수 있으니 이 점 양해 부탁 드립니다.

로그인 후, 문의하신 내용은 나의상담내역에서 조회하실 수 있습니다.

[접수 정보]

접수일시
답변받을 이메일

나의 상담내역 바로가기

음성서비스 신청

닫기

음성서비스 신청

[ 논문 정보 ]

[ 신청자 정보 ]

아이디
전화번호
- - SMS 및 카카오알림 동의
메일주소
작성하신 내용을 완료하시려면 [신청] 버튼을, 수정하시려면 [수정]버튼을 눌러주세요.

취소 음성서비스 신청 수정 신청

음성서비스 신청 확인

닫기

음성서비스 신청 확인

서비스 신청이 완료되었습니다.

신청하신 내역에 대한 처리 완료 시 메일로 별도 안내 드리도록 하겠습니다.

음성서비스 신청 증가 등의 이유로 처리가 다소 지연될 수 있으니, 이 점 양해 부탁드립니다.

감합니다.

[신청 정보]

신청일시
답변받을 이메일

41061 대구광역시 동구 동내로 64(동내동1119) KERIS빌딩

고객센터 (평일: 09:00 ~ 18:00)1599-3122

PC 버전 바로가기

회원가입

학술연구정보서비스 검색

MYRISS

회원서비스

About RISS

RISS 처음 방문 이세요?

고객센터

RISS 활용도 분석

최신/인기 학술자료

해외자료신청(E-DDS)

공지사항

해외전자정보서비스 검색

Databases & Journals

해외전자자료 이용안내

이용약관

닫기

학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)

제 1 장 총칙
1. 제 1 조 (목적)
  - 이 약관은 한국교육학술정보원(이하 "교육정보원"라 함)이 제공하는 학술연구정보서비스의 웹사이트(이하 "서비스" 라함)의 이용에 관한 조건 및 절차와 기타 필요한 사항을 규정하는 것을 목적으로 합니다.
2. 제 2 조 (약관의 효력과 변경)
  1. ① 이 약관은 서비스 메뉴에 게시하여 공시함으로써 효력을 발생합니다.
  2. ② 교육정보원은 합리적 사유가 발생한 경우에는 이 약관을 변경할 수 있으며, 약관을 변경한 경우에는 지체없이 "공지사항"을 통해 공시합니다.
  3. ③ 이용자는 변경된 약관사항에 동의하지 않으면, 언제나 서비스 이용을 중단하고 이용계약을 해지할 수 있습니다.
3. 제 3 조 (약관외 준칙)
  - 이 약관에 명시되지 않은 사항은 관계 법령에 규정 되어있을 경우 그 규정에 따르며, 그렇지 않은 경우에는 일반적인 관례에 따릅니다.
4. 제 4 조 (용어의 정의)
  이 약관에서 사용하는 용어의 정의는 다음과 같습니다.
  1. ① 이용자 : 교육정보원과 이용계약을 체결한 자
  2. ② 이용자번호(ID) : 이용자 식별과 이용자의 서비스 이용을 위하여 이용계약 체결시 이용자의 선택에 의하여 교육정보원이 부여하는 문자와 숫자의 조합
  3. ③ 비밀번호 : 이용자 자신의 비밀을 보호하기 위하여 이용자 자신이 설정한 문자와 숫자의 조합
  4. ④ 단말기 : 서비스 제공을 받기 위해 이용자가 설치한 개인용 컴퓨터 및 모뎀 등의 기기
  5. ⑤ 서비스 이용 : 이용자가 단말기를 이용하여 교육정보원의 주전산기에 접속하여 교육정보원이 제공하는 정보를 이용하는 것
  6. ⑥ 이용계약 : 서비스를 제공받기 위하여 이 약관으로 교육정보원과 이용자간의 체결하는 계약을 말함
  7. ⑦ 마일리지 : RISS 서비스 중 마일리지 적립 가능한 서비스를 이용한 이용자에게 지급되며, RISS가 제공하는 특정 디지털 콘텐츠를 구입하는 데 사용하도록 만들어진 포인트
제 2 장 서비스 이용 계약
1. 제 5 조 (이용계약의 성립)
  1. ① 이용계약은 이용자의 이용신청에 대한 교육정보원의 이용 승낙에 의하여 성립됩니다.
  2. ② 제 1항의 규정에 의해 이용자가 이용 신청을 할 때에는 교육정보원이 이용자 관리시 필요로 하는
    사항을 전자적방식(교육정보원의 컴퓨터 등 정보처리 장치에 접속하여 데이터를 입력하는 것을 말합니다)
    이나 서면으로 하여야 합니다.
  3. ③ 이용계약은 이용자번호 단위로 체결하며, 체결단위는 1 이용자번호 이상이어야 합니다.
  4. ④ 서비스의 대량이용 등 특별한 서비스 이용에 관한 계약은 별도의 계약으로 합니다.
2. 제 6 조 (이용신청)
  1. ① 서비스를 이용하고자 하는 자는 교육정보원이 지정한 양식에 따라 온라인신청을 이용하여 가입 신청을 해야 합니다.
  2. ② 이용신청자가 14세 미만인자일 경우에는 친권자(부모, 법정대리인 등)의 동의를 얻어 이용신청을 하여야 합니다.
3. 제 7 조 (이용계약 승낙의 유보)
  1. ① 교육정보원은 다음 각 호에 해당하는 경우에는 이용계약의 승낙을 유보할 수 있습니다.
    1. 1. 설비에 여유가 없는 경우
    2. 2. 기술상에 지장이 있는 경우
    3. 3. 이용계약을 신청한 사람이 14세 미만인 자로 친권자의 동의를 득하지 않았을 경우
    4. 4. 기타 교육정보원이 서비스의 효율적인 운영 등을 위하여 필요하다고 인정되는 경우
  2. ② 교육정보원은 다음 각 호에 해당하는 이용계약 신청에 대하여는 이를 거절할 수 있습니다.
    1. 1. 다른 사람의 명의를 사용하여 이용신청을 하였을 때
    2. 2. 이용계약 신청서의 내용을 허위로 기재하였을 때
4. 제 8 조 (계약사항의 변경)
  이용자는 다음 사항을 변경하고자 하는 경우 서비스에 접속하여 서비스 내의 기능을 이용하여 변경할 수 있습니다.
  1. ① 성명 및 생년월일, 신분, 이메일
  2. ② 비밀번호
  3. ③ 자료신청 / 기관회원서비스 권한설정을 위한 이용자정보
  4. ④ 전화번호 등 개인 연락처
  5. ⑤ 기타 교육정보원이 인정하는 경미한 사항
제 3 장 서비스의 이용
1. 제 9 조 (서비스 이용시간)
  - 서비스의 이용 시간은 교육정보원의 업무 및 기술상 특별한 지장이 없는 한 연중무휴, 1일 24시간(00:00-24:00)을 원칙으로 합니다. 다만 정기점검등의 필요로 교육정보원이 정한 날이나 시간은 그러하지 아니합니다.
2. 제 10 조 (이용자번호 등)
  1. ① 이용자번호 및 비밀번호에 대한 모든 관리책임은 이용자에게 있습니다.
  2. ② 명백한 사유가 있는 경우를 제외하고는 이용자가 이용자번호를 공유, 양도 또는 변경할 수 없습니다.
  3. ③ 이용자에게 부여된 이용자번호에 의하여 발생되는 서비스 이용상의 과실 또는 제3자에 의한 부정사용 등에 대한 모든 책임은 이용자에게 있습니다.
3. 제 11 조 (서비스 이용의 제한 및 이용계약의 해지)
  1. ① 이용자가 서비스 이용계약을 해지하고자 하는 때에는 온라인으로 교육정보원에 해지신청을 하여야 합니다.
  2. ② 교육정보원은 이용자가 다음 각 호에 해당하는 경우 사전통지 없이 이용계약을 해지하거나 전부 또는 일부의 서비스 제공을 중지할 수 있습니다.
    1. 1. 타인의 이용자번호를 사용한 경우
    2. 2. 다량의 정보를 전송하여 서비스의 안정적 운영을 방해하는 경우
    3. 3. 수신자의 의사에 반하는 광고성 정보, 전자우편을 전송하는 경우
    4. 4. 정보통신설비의 오작동이나 정보 등의 파괴를 유발하는 컴퓨터 바이러스 프로그램등을 유포하는 경우
    5. 5. 정보통신윤리위원회로부터의 이용제한 요구 대상인 경우
    6. 6. 선거관리위원회의 유권해석 상의 불법선거운동을 하는 경우
    7. 7. 서비스를 이용하여 얻은 정보를 교육정보원의 동의 없이 상업적으로 이용하는 경우
    8. 8. 비실명 이용자번호로 가입되어 있는 경우
    9. 9. 일정기간 이상 서비스에 로그인하지 않거나 개인정보 수집․이용에 대한 재동의를 하지 않은 경우
  3. ③ 전항의 규정에 의하여 이용자의 이용을 제한하는 경우와 제한의 종류 및 기간 등 구체적인 기준은 교육정보원의 공지, 서비스 이용안내, 개인정보처리방침 등에서 별도로 정하는 바에 의합니다.
  4. ④ 해지 처리된 이용자의 정보는 법령의 규정에 의하여 보존할 필요성이 있는 경우를 제외하고 지체 없이 파기합니다.
  5. ⑤ 해지 처리된 이용자번호의 경우, 재사용이 불가능합니다.
4. 제 12 조 (이용자 게시물의 삭제 및 서비스 이용 제한)
  1. ① 교육정보원은 서비스용 설비의 용량에 여유가 없다고 판단되는 경우 필요에 따라 이용자가 게재 또는 등록한 내용물을 삭제할 수 있습니다.
  2. ② 교육정보원은 서비스용 설비의 용량에 여유가 없다고 판단되는 경우 이용자의 서비스 이용을 부분적으로 제한할 수 있습니다.
  3. ③ 제 1 항 및 제 2 항의 경우에는 당해 사항을 사전에 온라인을 통해서 공지합니다.
  4. ④ 교육정보원은 이용자가 게재 또는 등록하는 서비스내의 내용물이 다음 각호에 해당한다고 판단되는 경우에 이용자에게 사전 통지 없이 삭제할 수 있습니다.
    1. 1. 다른 이용자 또는 제 3자를 비방하거나 중상모략으로 명예를 손상시키는 경우
    2. 2. 공공질서 및 미풍양속에 위반되는 내용의 정보, 문장, 도형 등을 유포하는 경우
    3. 3. 반국가적, 반사회적, 범죄적 행위와 결부된다고 판단되는 경우
    4. 4. 다른 이용자 또는 제3자의 저작권 등 기타 권리를 침해하는 경우
    5. 5. 게시 기간이 규정된 기간을 초과한 경우
    6. 6. 이용자의 조작 미숙이나 광고목적으로 동일한 내용의 게시물을 10회 이상 반복하여 등록하였을 경우
    7. 7. 기타 관계 법령에 위배된다고 판단되는 경우
5. 제 13 조 (서비스 제공의 중지 및 제한)
  1. ① 교육정보원은 다음 각 호에 해당하는 경우 서비스 제공을 중지할 수 있습니다.
    1. 1. 서비스용 설비의 보수 또는 공사로 인한 부득이한 경우
    2. 2. 전기통신사업법에 규정된 기간통신사업자가 전기통신 서비스를 중지했을 때
  2. ② 교육정보원은 국가비상사태, 서비스 설비의 장애 또는 서비스 이용의 폭주 등으로 서비스 이용에 지장이 있는 때에는 서비스 제공을 중지하거나 제한할 수 있습니다.
6. 제 14 조 (교육정보원의 의무)
  1. ① 교육정보원은 교육정보원에 설치된 서비스용 설비를 지속적이고 안정적인 서비스 제공에 적합하도록 유지하여야 하며 서비스용 설비에 장애가 발생하거나 또는 그 설비가 못쓰게 된 경우 그 설비를 수리하거나 복구합니다.
  2. ② 교육정보원은 서비스 내용의 변경 또는 추가사항이 있는 경우 그 사항을 온라인을 통해 서비스 화면에 공지합니다.
7. 제 15 조 (개인정보보호)
  1. ① 교육정보원은 공공기관의 개인정보보호에 관한 법률, 정보통신이용촉진등에 관한 법률 등 관계법령에 따라 이용신청시 제공받는 이용자의 개인정보 및 서비스 이용중 생성되는 개인정보를 보호하여야 합니다.
  2. ② 교육정보원의 개인정보보호에 관한 관리책임자는 학술연구정보서비스 이용자 관리담당 부서장(학술정보본부)이며, 주소 및 연락처는 대구광역시 동구 동내로 64(동내동 1119) KERIS빌딩, 전화번호 054-714-0114번, 전자메일 privacy@keris.or.kr 입니다. 개인정보 관리책임자의 성명은 별도로 공지하거나 서비스 안내에 게시합니다.
  3. ③ 교육정보원은 개인정보를 이용고객의 별도의 동의 없이 제3자에게 제공하지 않습니다. 다만, 다음 각 호의 경우는 이용고객의 별도 동의 없이 제3자에게 이용 고객의 개인정보를 제공할 수 있습니다.
    1. 1. 수사상의 목적에 따른 수사기관의 서면 요구가 있는 경우에 수사협조의 목적으로 국가 수사 기관에 성명, 주소 등 신상정보를 제공하는 경우
    2. 2. 신용정보의 이용 및 보호에 관한 법률, 전기통신관련법률 등 법률에 특별한 규정이 있는 경우
    3. 3. 통계작성, 학술연구 또는 시장조사를 위하여 필요한 경우로서 특정 개인을 식별할 수 없는 형태로 제공하는 경우
  4. ④ 이용자는 언제나 자신의 개인정보를 열람할 수 있으며, 스스로 오류를 수정할 수 있습니다. 열람 및 수정은 원칙적으로 이용신청과 동일한 방법으로 하며, 자세한 방법은 공지, 이용안내에 정한 바에 따릅니다.
  5. ⑤ 이용자는 언제나 이용계약을 해지함으로써 개인정보의 수집 및 이용에 대한 동의, 목적 외 사용에 대한 별도 동의, 제3자 제공에 대한 별도 동의를 철회할 수 있습니다. 해지의 방법은 이 약관에서 별도로 규정한 바에 따릅니다.
8. 제 16 조 (이용자의 의무)
  1. ① 이용자는 서비스를 이용할 때 다음 각 호의 행위를 하지 않아야 합니다.
    1. 1. 다른 이용자의 이용자번호를 부정하게 사용하는 행위
    2. 2. 서비스를 이용하여 얻은 정보를 교육정보원의 사전승낙없이 이용자의 이용이외의 목적으로 복제하거나 이를 출판, 방송 등에 사용하거나 제3자에게 제공하는 행위
    3. 3. 다른 이용자 또는 제3자를 비방하거나 중상모략으로 명예를 손상하는 행위
    4. 4. 공공질서 및 미풍양속에 위배되는 내용의 정보, 문장, 도형 등을 타인에게 유포하는 행위
    5. 5. 반국가적, 반사회적, 범죄적 행위와 결부된다고 판단되는 행위
    6. 6. 다른 이용자 또는 제3자의 저작권등 기타 권리를 침해하는 행위
    7. 7. 기타 관계 법령에 위배되는 행위
  2. ② 이용자는 이 약관에서 규정하는 사항과 서비스 이용안내 또는 주의사항을 준수하여야 합니다.
  3. ③ 이용자가 설치하는 단말기 등은 전기통신설비의 기술기준에 관한 규칙이 정하는 기준에 적합하여야 하며, 서비스에 장애를 주지 않아야 합니다.
9. 제 17 조 (광고의 게재)
  교육정보원은 서비스의 운용과 관련하여 서비스화면, 홈페이지, 전자우편 등에 광고 등을 게재할 수 있습니다.
제 4 장 서비스 이용 요금
1. 제 18 조 (이용요금)
  1. ① 서비스 이용료는 기본적으로 무료로 합니다. 단, 민간업체와의 협약에 의해 RISS를 통해 서비스 되는 콘텐츠의 경우 각 민간 업체의 요금 정책에 따라 유료로 서비스 합니다.
  2. ② 그 외 교육정보원의 정책에 따라 이용 요금 정책이 변경될 경우에는 온라인으로 서비스 화면에 게시합니다.
제 5 장 마일리지 정책
1. 제 19 조 (마일리지 정책의 변경)
  1. ① RISS 마일리지는 2017년 1월부로 모두 소멸되었습니다.
  2. ② 교육정보원은 마일리지 적립ㆍ사용ㆍ소멸 등 정책의 변경에 대해 온라인상에 공지해야하며, 최근에 온라인에 등재된 내용이 이전의 모든 규정과 조건보다 우선합니다.
제 6 장 저작권
1. 제 20 조 (게재된 자료에 대한 권리)
  서비스에 게재된 자료에 대한 권리는 다음 각 호와 같습니다.
  1. ① 게시물에 대한 권리와 책임은 게시자에게 있으며, 교육정보원은 게시자의 동의 없이는 이를 영리적 목적으로 사용할 수 없습니다.
  2. ② 게시자의 사전 동의가 없이는 이용자는 서비스를 이용하여 얻은 정보를 가공, 판매하는 행위 등 서비스에 게재된 자료를 상업적 목적으로 이용할 수 없습니다.
제 7 장 이의 신청 및 손해배상 청구 금지
1. 제 21 조 (이의신청금지)
  이용자는 교육정보원에서 제공하는 서비스 이용시 발생되는 어떠한 문제에 대해서도 무료 이용 기간 동안은 이의 신청 및 민원을 제기할 수 없습니다.
2. 제 22 조 (손해배상청구금지)
  이용자는 교육정보원에서 제공하는 서비스 이용시 발생되는 어떠한 문제에 대해서도 무료 이용 기간 동안은 교육정보원 및 관계 기관에 손해배상 청구를 할 수 없으며 교육정보원은 이에 대해 책임을 지지 아니합니다.
부칙
이 약관은 2000년 6월 1일부터 시행합니다.
부칙(개정 2005. 5. 31)
이 약관은 2005년 5월 31일부터 시행합니다.
부칙(개정 2010. 1. 1)
이 약관은 2010년 1월 1일부터 시행합니다.
부칙(개정 2010. 4 1)
이 약관은 2010년 4월 1일부터 시행합니다.
부칙(개정 2017. 1 1)
이 약관은 2017년 1월 1일부터 시행합니다.

학술연구정보서비스 개인정보처리방침

Ver 8.6 (2023년 1월 31일 ~ )

닫기

학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.

주요 개인정보 처리 표시(라벨링)

처리 목적
보유 기간
처리 항목
개인 정보
제3자 제공
처리 위탁
파기
정보주체의 권리의무
안전성확보조치
자동화 수집
개인정보보호책임자
열람 청구
권익침해 구제
추가적 이용
처리방침 변경

목 차

제1조(개인정보의 처리 목적)
제2조(개인정보의 처리 및 보유 기간)
제3조(처리하는 개인정보의 항목)
제4조(개인정보파일 등록 현황)
제5조(개인정보의 제3자 제공)
제6조(개인정보 처리업무의 위탁)
제7조(개인정보의 파기 절차 및 방법)
제8조(정보주체와 법정대리인의 권리·의무 및 그 행사 방법)
제9조(개인정보의 안전성 확보조치)
제10조(개인정보 자동 수집 장치의 설치·운영 및 거부)
제11조(개인정보 보호책임자)
제12조(개인정보의 열람청구를 접수·처리하는 부서)
제13조(정보주체의 권익침해에 대한 구제방법)
제14조(추가적 이용·제공 판단기준)
제15조(개인정보 처리방침의 변경)

제1조(개인정보의 처리 목적)

RISS는 개인정보를 다음의 목적을 위해 처리합니다. 처리하고 있는 개인정보는 다음의 목적 이외의 용도로는 이용되지 않으며, 이용 목적이 변경되는 경우에는 「개인정보 보호법」 제18조에 따라 별도의 동의를 받는 등 필요한 조치를 이행할 예정입니다.

가. 서비스 제공
     - 콘텐츠 제공, 문헌배송 및 결제, 요금정산 등 서비스 제공
나. 회원관리
     - 회원제 서비스 이용에 따른 본인확인,
     - 만14세 미만 아동 개인 정보 수집 시 법정 대리인 동의여부 확인, 추후 법정 대리인 본인확인
     - 분쟁 조정을 위한 기록보존, 불만처리 등을 위한 원활한 의사소통 경로의 확보, 공지사항 전달
다. 서비스 개선
     - 신규 서비스 개발 및 특화
     - 통계학적 특성에 따른 서비스 제공 및 광고 게재, 이벤트 등 정보 전달 및 참여 기회 제공
     - 서비스 이용에 대한 통계

제2조(개인정보의 처리 및 보유 기간)

가. 처리기간 및 보유 기간:

3년

또는 회원탈퇴시까지
나. 다만, 다음의 사유에 해당하는 경우에는 해당 사유 종료시 까지 정보를 보유 및 열람합니다.
     ▶ 신청 중인 서비스가 완료 되지 않은 경우
          - 보존 이유 : 진행 중인 서비스 완료(예:원문복사 등)
          - 보존 기간 : 서비스 완료 시까지
          - 열람 예정 시기 : 수시(RISS에서 신청된 서비스의 처리내역 및 진행상태 확인 요청 시)
     ▶ 관련법령에 의한 정보보유 사유 및 기간
          - 대금결제 및 재화 등의 공급에 관한 기록 :

5년

(「전자상거래 등에서의 소비자보호에 관한
법률」 제 6조 및 시행령 제 6조)
- 소비자의 불만 또는 분쟁 처리에 관한 기록 :

3년

(「전자상거래 등에서의 소비자보호에 관한
법률」 제 6조 및 시행령 제 6조)
- 접속에 관한 기록 :

2년

이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)

제3조(처리하는 개인정보의 항목)

가. 필수 항목 : ID, 이름, 생년월일, 신분(직업구분), 이메일, 소속분야,
보호자 성명(어린이회원), 보호자 이메일(어린이회원)
나: 선택 항목 : 소속기관명, 학과/부서명, 학번/직원번호, 전화, 주소, 장애인 여부
다. 자동수집항목 : IP주소, ID, 서비스 이용기록, 방문기록

제4조(개인정보파일 등록 현황)


개인정보파일의 명칭	운영근거 / 처리목적	개인정보파일에 기록되는 개인정보의 항목		보유기간
학술연구정보서비스 이용자 가입정보 파일	한국교육학술정보원법	필수	ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부	3년 또는 탈퇴시
학술연구정보서비스 이용자 가입정보 파일	한국교육학술정보원법	선택	소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소	3년 또는 탈퇴시

제5조(개인정보의 제3자 제공)

가. RISS는 원칙적으로 정보주체의 개인정보를 제1조(개인정보의 처리 목적)에서 명시한 범위 내에서
     처리하며, 정보주체의 사전 동의 없이는 본래의 범위를 초과하여 처리하거나 제3자에게 제공하지
     않습니다. 단, 정보주체의 동의, 법률의 특별한 규정 등 개인정보 보호법 제17조 및 제18조에 해당하는
     경우에만 개인정보를 제3자에게 제공합니다.
나. RISS는 원활한 서비스 제공을 위해 다음의 경우 정보주체의 동의를 얻어 필요 최소한의 범위로만
     제공합니다.
     - 복사/대출 배송 서비스를 위해서 아래와 같이 개인정보를 제공합니다.
          1. 개인정보 제공 대상 : 제공도서관, ㈜이니시스(선불결제 시)
          2. 개인정보 제공 목적 : 복사/대출 서비스 제공
          3. 개인정보 제공 항목 : 이름, 전화번호, 이메일
          4. 개인정보 보유 및 이용 기간 : 신청건 발생일 후 5년
▶ 개인정보 제공에 동의하지 않을 권리가 있으며, 거부하는 경우 서비스 이용이 불가합니다.

제6조(개인정보 처리업무의 위탁)

RISS는 원활한 개인정보 업무처리를 위하여 다음과 같이 개인정보 처리업무를 위탁하고 있습니다.

가. 위탁하는 업무 내용 : 회원 개인정보 처리
나. 수탁업체명 : ㈜퓨쳐누리

RISS는 위탁계약 체결 시 「개인정보 보호법」 제26조에 따라 위탁업무 수행 목적 외 개인정보 처리금지, 안전성 확보조치, 재위탁 제한, 수탁자에 대한 관리·감독, 손해배상 등 책임에 관한 사항을 계약서 등 문서에 명시하고, 수탁자가 개인정보를 안전하게 처리하는지를 감독하고 있습니다.

위탁업무의 내용이나 수탁자가 변경될 경우에는 지체 없이 본 개인정보 처리방침을 통하여 공개하도록 하겠습니다.

제7조(개인정보의 파기 절차 및 방법)

가. 파기절차
     - 개인정보의 파기 : 보유기간이 경과한 개인정보는 종료일로부터 지체 없이 파기
     - 개인정보파일의 파기 : 개인정보파일의 처리 목적 달성, 해당 서비스의 폐지, 사업의 종료 등 그
      개인정보파일이 불필요하게 되었을 때에는 개인정보의 처리가 불필요한 것으로 인정되는 날로부터
      지체 없이 그 개인정보파일을 파기.
나. 파기방법
     - 전자적 형태의 정보는 기록을 재생할 수 없는 기술적 방법을 사용하여 파기.
     - 종이에 출력된 개인정보는 분쇄기로 분쇄하거나 소각을 통하여 파기.

제8조(정보주체와 법정대리인의 권리·의무 및 그 행사 방법)

정보주체(만 14세 미만인 경우에는 법정대리인을 말함)는 개인정보주체로서 다음과 같은 권리를 행사할 수 있습니다.
가. 권리 행사 항목 및 방법
     - 권리 행사 항목: 개인정보 열람 요구, 오류 정정 요구, 삭제 요구, 처리정지 요구
     - 권리 행사 방법: 개인정보 처리 방법에 관한 고시 별지 제8호(대리인의 경우 제11호) 서식에 따라
      작성 후 서면, 전자우편, 모사전송(FAX), 전화, 인터넷(홈페이지 고객센터) 제출
나. 개인정보 열람 및 처리정지 요구는 「개인정보 보호법」 제35조 제5항, 제37조 제2항에 의하여
      정보주체의 권리가 제한 될 수 있음
다. 개인정보의 정정 및 삭제 요구는 다른 법령에서 그 개인정보가 수집 대상으로 명시되어 있는 경우에는
      그 삭제를 요구할 수 없음
라. RISS는 정보주체 권리에 따른 열람의 요구, 정정·삭제의 요구, 처리정지의 요구 시
      열람 등 요구를 한 자가 본인이거나 정당한 대리인인지를 확인함.
마. 정보주체의 권리행사 요구 거절 시 불복을 위한 이의제기 절차는 다음과 같습니다.
     1) 해당 부서에서 열람 등 요구에 대한 연기 또는 거절 시 요구 받은 날로부터 10일 이내에 정당한 사유
        및 이의제기 방법 등을 통지
     2) 해당 부서에서 정보주체의 이의제기 신청 및 접수(서면, 유선, 이메일 등)하여 개인정보보호 담당자가
        내용 확인
     3) 개인정보관리책임자가 처리결과에 대한 최종 검토
     4) 해당부서에서 정보주체에게 처리결과 통보
*. [교육부 개인정보 보호지침 별지 제1호] 개인정보 (열람, 정정·삭제, 처리정지) 요구서
*. [교육부 개인정보 보호지침 별지 제2호] 위임장

제9조(개인정보의 안전성 확보조치)

가. 내부관리계획의 수립 및 시행 : RISS의 내부관리계획 수립 및 시행은 한국교육학술정보원의 내부
      관리 지침을 준수하여 시행.
나. 개인정보 취급 담당자의 최소화 및 교육
     - 개인정보를 취급하는 분야별 담당자를 지정․운영
     - 한국교육학술정보원의 내부 관리 지침에 따른 교육 실시
다. 개인정보에 대한 접근 제한
     - 개인정보를 처리하는 데이터베이스시스템에 대한 접근권한의 부여, 변경, 말소를 통하여
     개인정보에 대한 접근통제 실시
     - 침입차단시스템, ID/패스워드 및 공인인증서 확인을 통한 접근 통제 등 보안시스템 운영
라. 접속기록의 보관 및 위변조 방지
     - 개인정보처리시스템에 접속한 기록(웹 로그, 요약정보 등)을 2년 이상 보관, 관리
     - 접속 기록이 위변조 및 도난, 분실되지 않도록 보안기능을 사용
마. 개인정보의 암호화 : 이용자의 개인정보는 암호화 되어 저장 및 관리
바. 해킹 등에 대비한 기술적 대책
     - 보안프로그램을 설치하고 주기적인 갱신·점검 실시
     - 외부로부터 접근이 통제된 구역에 시스템을 설치하고 기술적/물리적으로 감시 및 차단
사. 비인가자에 대한 출입 통제
     - 개인정보를 보관하고 있는 개인정보시스템의 물리적 보관 장소를 별도 설치․운영
     - 물리적 보관장소에 대한 출입통제, CCTV 설치․운영 절차를 수립, 운영

제10조(개인정보 자동 수집 장치의 설치·운영 및 거부)

가. 정보주체의 이용정보를 저장하고 수시로 불러오는 ‘쿠키(cookie)’를 사용합니다.
나. 쿠키는 웹사이트를 운영하는데 이용되는 서버(http)가 이용자의 컴퓨터브라우저에게 보내는 소량의
     정보이며 이동자들의 PC 컴퓨터내의 하드디스크에 저장되기도 합니다.
     1) 쿠키의 사용목적 : 이용자에게 보다 편리한 서비스 제공하기 위해 사용됩니다.
     2) 쿠키의 설치·운영 및 거부 : 브라우저 옵션 설정을 통해 쿠키 허용, 쿠키 차단 등의 설정을 할 수
          있습니다.
          - Internet Explorer : 웹브라우저 우측 상단의 도구 메뉴 > 인터넷 옵션 > 개인정보 > 설정 > 고급
          - Edge : 웹브라우저 우측 상단의 설정 메뉴 > 쿠키 및 사이트 권한 > 쿠키 및 사이트 데이터
             관리 및 삭제
          - Chrome : 웹브라우저 우측 상단의 설정 메뉴 > 보안 및 개인정보 보호 > 쿠키 및 기타 사이트
             데이터
     3) 쿠키 저장을 거부 또는 차단할 경우 서비스 이용에 어려움이 발생할 수 있습니다.

제11조(개인정보 보호책임자)

가. RISS는 개인정보 처리에 관한 업무를 총괄해서 책임지고, 개인정보 처리와 관련한 정보주체의
불만처리 및 피해구제 등을 위하여 아래와 같이 개인정보 보호책임자를 지정하고 있습니다.


구분	담당자	연락처
KERIS 개인정보 보호책임자	정보보호본부 김태우	- 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195
KERIS 개인정보 보호담당자	개인정보보호부 이상엽
RISS 개인정보 보호책임자	대학학술본부 장금연	- 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194
RISS 개인정보 보호담당자	학술진흥부 길원진

나. 정보주체는 RISS의 서비스(또는 사업)을 이용하시면서 발생한 모든 개인정보 보호 관련 문의, 불만처리,
피해구제 등에 관한 사항을 개인정보 보호책임자 및 담당부서로 문의 할 수 있습니다.
RISS는 정보주체의 문의에 대해 답변 및 처리해드릴 것입니다.

제12조(개인정보의 열람청구를 접수·처리하는 부서)

가. 자체 개인정보 열람청구 접수ㆍ처리 창구
     부서명 : 대학학술본부/학술진흥부
     담당자 : 길원진
     이메일 : giltizen@keris.or.kr
     전화번호 : 053-714-0149
     팩스번호 : 053-714-0194
나. 개인정보 열람청구 접수ㆍ처리 창구
     - 개인정보보호 포털 웹사이트(www.privacy.go.kr)
     - 개인정보보호 포털 → 민원마당 → 개인정보 열람 등 요구(본인확인을 위한
       휴대전화·아이핀(I-PIN) 등이 있어야 함)

제13조(정보주체의 권익침해에 대한 구제방법)

‣ 정보주체는 개인정보침해로 인한 구제를 받기 위하여 개인정보분쟁조정위원회, 한국인터넷진흥원
   개인정보침해신고센터 등에 분쟁해결이나 상담 등을 신청할 수 있습니다. 이 밖에 기타 개인정보
   침해의 신고, 상담에 대하여는 아래의 기관에 문의하시기 바랍니다.

   가. 개인정보분쟁조정위원회 : (국번없이) 1833-6972(www.kopico.go.kr)
   나. 개인정보침해신고센터 : (국번없이) 118(privacy.kisa.or.kr)
   다. 대검찰청 : (국번없이) 1301 (www.spo.go.kr)
   라. 경찰청 : (국번없이) 182 (ecrm.cyber.go.kr)

‣RISS는 정보주체의 개인정보자기결정권을 보장하고, 개인정보침해로 인한 상담 및 피해 구제를
    위해 노력하고 있으며, 신고나 상담이 필요한 경우 아래의 담당부서로 연락해 주시기 바랍니다.
   ▶ 개인정보 관련 고객 상담 및 신고
      부서명 : 학술진흥부
      담당자 : 길원진
      연락처 : ☎053-714-0149 / (Mail) giltizen@keris.or.kr / (Fax) 053-714-0194
‣「개인정보 보호법」제35조(개인정보의 열람), 제36조(개인정보의 정정·삭제), 제37조(개인정보의
   처리정지 등)의 규정에 의한 요구에 대하여 공공기관의 장이 행한 처분 또는 부작위로 인하여 권리
   또는 이익의 침해를 받은 자는 행정심판법이 정하는 바에 따라 행정심판을 청구할 수 있습니다.
   ※ 행정심판에 대해 자세한 사항은 중앙행정심판위원회(www.simpan.go.kr) 홈페이지를 참고
   하시기 바랍니다.

제14조(추가적인 이용ㆍ제공 판단기준)

RISS는 「개인정보 보호법」제15조제3항 및 제17조제4항에 따라 「개인정보 보호법 시행령」
제14조의2에 따른 사항을 고려하여 정보주체의 동의 없이 개인정보를 추가적으로 이용 · 제공할 수 있습니다.
이에 따라 RISS는 정보주체의 동의 없이 추가적인 이용 · 제공을 하는 경우, 본 개인정보처리방침을
통해 아래와 같은 추가적인 이용 · 제공을 위한 고려사항에 대한 판단기준을 안내드리겠습니다.
     ▶ 개인정보를 추가적으로 이용 · 제공하려는 목적이 당초 수집 목적과 관련성이 있는지 여부
     ▶ 개인정보를 수집한 정황 또는 처리 관행에 비추어 볼 때 추가적인 이용 · 제공에 대한 예측
          가능성이 있는지 여부
     ▶ 개인정보의 추가적인 이용 · 제공이 정보주체의 이익을 부당하게 침해하는지 여부
     ▶ 가명처리 또는 암호화 등 안전성 확보에 필요한 조치를 하였는지 여부

제15조(개인정보 처리방침의 변경)

RISS는 「개인정보 보호법」제30조에 따라 개인정보 처리방침을 변경하는 경우 정보주체가 쉽게
확인할 수 있도록 홈페이지에 공개하고 변경이력을 관리하고 있습니다.
‣ 이 개인정보처리방침은 2023. 1. 31. 부터 적용됩니다.
‣ 이전의 개인정보처리방침은 상단에서 확인할 수 있습니다.

닫기

변경하기 다음에 변경하기 1개월후 변경하기

자동로그아웃 안내

닫기

인증오류 안내

닫기

귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.

(참조 : RISS 이용약관 및 개인정보처리방침)

신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.

- 기존 아이디 재사용 불가

휴면계정 안내

RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.

(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)

휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.

고객센터 1599-3122

ARS번호+1번(회원가입 및 정보수정)

내보내기 형태를 선택하세요

서지정보의 형식을 선택하세요

EndNote 및 Mendeley 소개

RefWorks 소개

[ 논문 정보 ]

[ 신청자 정보 ]

[ 논문 정보 ]

[ 신청자 정보 ]

제 1 장 총칙

제 1 조 (목적)

제 2 조 (약관의 효력과 변경)

제 3 조 (약관외 준칙)

제 4 조 (용어의 정의)

제 2 장 서비스 이용 계약

제 5 조 (이용계약의 성립)

제 6 조 (이용신청)

제 7 조 (이용계약 승낙의 유보)

제 8 조 (계약사항의 변경)

제 3 장 서비스의 이용

제 9 조 (서비스 이용시간)

제 10 조 (이용자번호 등)

제 11 조 (서비스 이용의 제한 및 이용계약의 해지)

제 12 조 (이용자 게시물의 삭제 및 서비스 이용 제한)

제 13 조 (서비스 제공의 중지 및 제한)

제 14 조 (교육정보원의 의무)

제 15 조 (개인정보보호)

제 16 조 (이용자의 의무)

제 17 조 (광고의 게재)

제 4 장 서비스 이용 요금

제 18 조 (이용요금)

제 5 장 마일리지 정책

제 19 조 (마일리지 정책의 변경)

제 6 장 저작권

제 20 조 (게재된 자료에 대한 권리)

제 7 장 이의 신청 및 손해배상 청구 금지

제 21 조 (이의신청금지)

제 22 조 (손해배상청구금지)

부칙

부칙(개정 2005. 5. 31)

부칙(개정 2010. 1. 1)

부칙(개정 2010. 4 1)

부칙(개정 2017. 1 1)

Ver 8.6 (2023년 1월 31일 ~ )